Supplement: Thousands of human mobile element fragments undergo strong purifying selection near developmental genes

Craig B Lowe *, Gill Bejerano †*, and David Haussler * ‡

*Center for Biomolecular Science and Engineering University of California Santa Cruz, Santa Cruz, CA 95064, USA, and [‡]Howard Hughes Medical Institute

Submitted to Proceedings of the National Academy of Sciences of the United States of America

Supplemental material

Supplemental text, tables, and figures.

S1 pan-boreoeutherian mobile elements

Mobile elements, as annotated by Repbase [1] and Repeat-Masker [2], have a hierarchical naming convention where they are first broken down into classes, then families, and finally subfamilies. In the main text we define "pan-boreoeutherian" subfamilies to be the subfamilies that are present in primates (human, chimp, or rhesus), rodents (rat or mouse), and carnivores (dog). Having a presence in all three of the subtrees means that the mobile element subfamily either predated, or was alive at the time of the boreoeutherian ancestor. These were the only subfamilies used in our study since mobile elements would have to be this old to deposit conserved nonexonic elements (CNEs) that were present in the boreoeutherian ancestor. Figure S1 may aid in visualizing the location of the boreoeutherian ancestor in relation to sequenced extant species.

All these pan-boreoeutherian subfamilies can be grouped at the family and class level to show which types of mobile elements are contributing the most (Table S1). LINEs and SINEs appear to be contributing the majority of the CNEs. This data set can also be shown at the subfamily level and in Table S2 we show the 50 subfamilies that have contributed the most CNEs in our survey. In Table S3 we show the top 50 subfamilies, ranked by how many CNEs they have contributed, in relation to their overall genomic abundance. These subfamilies tend to be older, since this allows for their neutral copies to have drifted far enough from the consensus to be unrecognizable in the extant species.

S2 formal definitions for enrichment tests

Our first enrichment test assigns exaptations to the closest gene TSS within 1Mb and uses the binomial distribution, for which we must define three parameters:

x = number of successes This is the number of genes with the given annotation (either a GO term or a pathway name) that were selected by an exaptation.

n = number of trials This is the number of chances to get a success, so we use the number of exaptations.

p=probability of success To define the probability of success we divide the number of bases in the genome that closest to a TSS with the given annotation, and divide that number by

the total number of bases in the genome.

Our second enrichment test assigns exaptations to the closest gene TSS within 1Mb and uses the hypergeometric distribution, for which we must define four parameters:

x = number of successes This is the number of genes with the given annotation that were selected by an exaptation.

n=number of ball sinthehat This is the number of genes that had GO annotation.

m = number of ball scolored for success This is the number of genes that have been assigned the given annotation being tested for enrichment.

k = thenumber of draws This is the number of genes that were assigned an exaptation.

Our third enrichment test assigns repeat elements (both those identified as exapted and those not) to gene TSSs. We then "pick" the exapted repeat elements and see if they are enriched for an annotation compared to the repeat element background. For this we use the hypergeometric distribution and need to define four parameters:

x = number of successes This is the number of repeat instances that were exapted and assigned to a gene with the given annotation.

n = number of ball sin the hat Number of repeat elements.

m = number of ball scolored for success Number of repeat elements that have been assigned to a gene with the given annotation

k=thenumber of draws Number of repeat elements that have been both exapted and assigned to a gene with the given annotation.

S3 enrichment results for GO and pathways

As described in the main text, the striking enrichment is for terms related to transcription regulation and development. A more specific category that we see quite often is cell-adhesion and its related terms. In Figure S4 through Figure S15 we have shown the most enriched GO terms and colored them to help the reader visualize these strong enrichments. We not only looked at our set as a whole, but also investigated the

The authors declare no conflict of interest.

This paper was submitted directly to the PNAS office.

 $^{^\}dagger$ To whom correspondence should be addressed.E-mail: bejerano@stanford.edu. New address: Depts. of Developmental Biology and Computer Science, Stanford University, Stanford, CA 94305, USA

^{©2006} by The National Academy of Sciences of the USA

enrichment at every level of the repeat taxonomy provided to us: classes, families, and subfamilies.

The pathway annotation is far more sparse than GO, but top enrichments for the entire set are shown in Table S17 and top results for classes, families, and subfamilies are present in Table S18. We used pathway datasets from Biocarta [6], Kegg [7], and Genmapp [8]. The p-values reported are from the test that assumes a uniform distribution over genes and does not allow the same gene to be selected multiple times. We use this test because it might be misleading to say we are enriched for a pathway of 30 genes if 20 exapted elements are all near a single gene in the pathway.

We believe that enrichment for pathways will be a very insightful way to examine sets of cis-regulatory regions in the future, but currently the annotation is too sparse. We suspect that many of these regions, from the same consensus, may drive expression at similar time points. We would not expect the genes they are near to all have a similar function (as specific GO terms usually show), but we would expect many of them to be in the same or related pathways. We followed up on MIRb elements being near all genes known to be in the pathway dealing with the reception of the RELN signal. We looked for conserved transcription factor binding sites (detailed in the main text), and an example of engrailed binding sites is shown in Figure S3.

S4 clouds of exaptations

During the enrichment tests it become clear that the elements do indeed form large clusters near certain genes (Figure 4, Table S16). We investigated if these clouds of exaptations contained similar sequences or dissimilar sequences. Are these genes exapting many of a certain kind of repeat, or are they looking to grab one of each? We calculated both the entropy and relative entropy of these exaptation clouds. For the relative entropy calculation we used the background distribution of all exaptations identified in this study. In Table S28 we show both the entropies as well as a p-value of getting an entropy that high with the given number of elements in the cloud.

S5 overlap with verified gene regulatory elements

Our set of conserved nonexonic elements (CNEs) was created with the intention of being putative gene regulatory elements. To investigate if any of these regions have already been experimentally validated as developmental enhancers, we checked to see if there was overlap between any of our elements and those validated in the Enhancer Browser [4].

We found that three of the exapted regions are covered by verified enhancers, but the regions of DNA that were validated where typically 10 times larger than the exaptation, so it is not clear if the exapted region is fully, or even partially responsible for the enhancer activity. The locations of these exaptations and the size of the verified regions is available in Table S19.

S6 overlap with previously unknown transcription start

sites

CAGE sequencing allows the first approximately 20 bases of an mRNA to be sequenced so that the transcription start site may be identified. When a large set of CAGE tags was published and made publicly available [5] we investigated if our putative cis-regulatory elements could be acting as distal transcription start sites that may be tissue or time specific. This would be a different mechanism than cis-regulation, but in the end it would have a similar effect of driving gene expression at a specific time and/or in a specific tissue.

We utilized both the human and mouse CAGE tags. The mouse tags were first mapped to syntenic locations in the human genome for analysis. All previously known coding regions were filtered out of the CAGE tags so that only the new putative start sites remained. We examined the overlap of the remaining CAGE tags with our set of exapted elements and found 297 exaptations that are overlapped by CAGE tags. This is only an enrichment of 1.3x, which leads us to believe that most of these overlaps are by chance; randomly selecting noncoding regions in the genome would have comparative results. A few of these regions could be functioning as previously unknown transcription start sites, but there is no strong bias towards a certain repeat family or certain tissue type. The number of overlaps can be seen in Table S20.

Tags that could not be mapped uniquely to the genome did not appear in the final set, which biases strongly against mobile elements. We hope that in the future advanced methods will allow experimentalists to deal with interspersed repeats so that the true contribution of these elements may be fully realized.

S7 enrichment for exaptations that have conserved the same section of the consensus

By comparing the regions of a repeat consensus that were being exapted versus the genomic abundance of that section, we were able to see that certain portions of the repeat are much more likely to be exapted as CNEs (Figure 2, Figure S2). We then investigated if the exapted elements that contributed to each peak may be enriched for a certain GO term or pathway. This would be circumstantial evidence that exaptations from similar sections of the consensus have similar functions. Table S21 and Table S22 show the enrichments for these tests, but no convincing enrichments were found. We look forward to more extensive pathway annotation in the future.

S8 enrichment for groups of exaptations defined by sequence similarity

Many mobile elements in the genome are chimeras so very similar sequences are often present in different families [9]. For this reason we examined groups of exapted elements where every member of the group has close sequence similarity to all other members in the group.

To do this we did an all-by-all sequence comparison of the exapted elements. This dataset allowed us to create a graph where each exaptation is represented by a node and two nodes (exaptations) are connected by an edge if the sequence alignment between the two is above a given significance threshold. We found the largest fully connected cliques in this graph. A clique is a section of the graph where each nodes is directly connected to every other node in the section. The nodes in the clique will give us a set of exaptations where each element is highly similar, at the sequence level, to all the other ele-

ments. Table S23 shows the cliques that we discovered and used in further analysis.

We expect that these groups of exaptations may have similar function because of their close sequence identity. To explore this idea we looked to GO and pathway enrichments for these groupings. The results of the GO analysis assuming a uniform distribution over the genome and a uniform distribution over genes can be seen in Table S24 and Table S25. The pathway results for the same null distributions can be seen in Table S26 and Table S27.

S9 vanishing repeat families

When conducting this survey we faced the problem that a sequence may have been deposited by a mobile element so long ago in the human lineage that we no longer recognize the sequence as coming from a mobile element. Once all members of a mobile element family cease to replicate, it is only a matter of time before the instances decay away beyond recognition and it is no longer evident that the interspersed repeat ever existed. We conducted a simulation to quantify how long ago a repeat family would have needed to cease replicating in order for it to go unnoticed in the extant human genome.

Repeats are often identified because researchers notice that a section of the genome has a number of seemingly paralogous sequences. These sequences are then aligned to each other to generate a consensus sequence, which is used as the most likely sequence of the ancient repeat. This consensus can then be used to iteratively find more elements and refine the consensus. If enough time has gone by then only a few of the sequences will have a significant alignment to each other and the family will not be identified. In a recent paper a repeat was identified in human, only after being found at very high copy number in Coelacanth [10]. This SINE, the LF-SINE, had never been reconstructed and annotated in human, even though there is a region in human that has 34 significant alignments to other regions in the human genome. We use the term "pile-up" to describe a region of the genome that has many significant alignments to other sequence in the genome. The largest pile-up of all the LF-SINE instances in human was a pile-up of 34. We use this statistic, that regions seem to need more than 34 paralogous copies in the genome before they will be annotated based on human sequence, to quantify how recently a mobile element must have been alive for us to recognize it in human. Our calculations will give us the expected maximum pile-up in the genome for a repeat family based on the branch length from when it stopped replicating to the extant genome, as well as the number of copies in the genome when replication stopped. If the expected maximum pile-up is under 35 then we label this repeat as having disappeared.

We begin by calculating the chances that two identical sequences will align to each other after they have both undergone a specified distance of independent evolution. This tells us, given that two sequences (repeats) in the genome were identical at a certain time in evolution, what are the chances that they will give significant alignments in the extant genome, providing that they have been under neutral selection. For each branch length from 0 to 1 with a step of 0.2, we did 1,000,000 trials of taking two sequences and decaying each for the specified branch length and recording if they gave a significant alignment. We used the MIR_Mars

263 base-pair consensus sequence since paralogous alignments must be to the same regions of the sequence to make it apparent that a unit is repeated in the genome. Longer elements, such as LINEs, are more complicated since they may have 20 or more non-overlapping 250 base windows, only one of these needs to have a large pile-up to have the element partially detected, but all would need to have pile-ups to have the element be completely detected. By using a shorter repeat we simplified these issues since the repeat will either be almost entirely found, or not found at all. This simulation gave us the probability that two sequences will align, given that they have both decayed for a specified branch length.

To expand this to a family of N elements we use a simplifying assumption that all comparisons are independent and we model the density function as a binomial with the probability taken from the simulation and the number of trials being the number of family members minus one, N-1. This binomial distribution gives the probability density for a given pile-up in the genome, from a family of size N, that stopped replicating at a certain point on the human lineage. To know what the probability of this single pile-up being greater than or equal to some value, Y, we can sum the discrete probability density from Y to N-1. Because we care if any of the N members of the family have a pile-up greater than Y, and not only a single instance, we make a second simplifying assumption that alignments between family members are also independent and we can now multiply the probability of a single instance giving us a pile-up of Y or greater by N to get the probability of any member of the family giving us a pile-up greater than or equal to Y.

$$p(maxPileUp >= Y) = min(1, N \cdot \sum_{i=Y}^{N-1} B(i; N-1, p))$$

For branch lengths up to 1 substitution per site and repeat population sizes up to one million, we show in Figure S4 the surface for what the largest expected pile-up in the genome is

$$largestPileUp = \operatorname*{argmax}_{k}(N \cdot \sum_{i=k}^{N-1} B(i; N-1, p)) > 0.5)$$

If a repeat stopped jumping near the split with dog, there will probably be an instance in the genome that aligns to just about all copies. If the mobile element stopped proliferating around the time of the human opossum split, there will still be clear evidence of the family, but the pile-ups will be much smaller than the original family size. For repeats this old, a researcher will have to reconstruct a consensus and then search again to realize the extent of the repeat's proliferation. Families that died at the time of the human-chicken speciation are most likely the furthest back that we can currently see. After this, the pile-ups left in the genome will be smaller than 35 and will probably not have been noticed and reconstructed at this time, as evidenced by the LF-SINE not being annotated until a few Coelacanth sequences were made public. To annotate mobile elements that died before the human-chicken split, researchers would have to either notice the repeat first in a species with a slower mutation rate, or a significant number of instances would need to be under negative selection to slow their mutation rate.

- 1. Jurka J (2000) Trends Genet 16:418-420.
- 2. Smit A, Green P (2005) http://ftp.genome.washington.edu/RM/RepeatMasker.html.
- Kamal M, Xie X, Lander ES (2006) Proc Natl Acad Sci U S A 103:2740– 2745.
- 4. Visel A, Minovitsky S, Dubchak I, Pennacchio LA (2007) Nucleic Acids Res $35{:}88{-}92.$
- Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, Ponjavic J, Semple CAM, Taylor MS, Engstrom PG, Frith MC, Forrest ARR, Alkema WB, Tan SL, Plessy C, Kodzius R, Ravasi T, Kasukawa T, Fukuda S, Kanamori-Katayama M, Kitazume Y, Kawaji H, Kai C, Nakamura M, Konno H, Nakano K, Mottagui-Tabar S, Arner P, Chesi A, Gustincich S, Persichetti F, Suzuki H, Grimmond SM, Wells CA, Orlando V, Wahlestedt C, Liu ET, Harbers M, Kawai J, Bajic VB, Hume DA, Hayashizaki Y (2006) Nat Genet 38:626-635.
- 6. BioCarta . (2006) http://www.biocarta.com.
- Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M (2004) Nucleic Acids Res 32:277–280.
- 8. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR (2002) Nat Genet 31:19–20. Letter t:tter.
- 9. Zhi D, Raphael BJ, Price AL, Tang H, Pevzner PA (2006) $Genome\ Biol\ 7:R7.$
- 10. Bejerano G, Lowe CB, Ahituv N, King B, Siepel A, Salama SR, Rubin EM, Kent WJ, Haussler D (2006) Nature 441:87–90.
- 11. Nishihara H, Terai Y, Okada N (2002) Mol Biol Evol 19:1964–1972.
- Deininger PL, Moran JV, Batzer MA, Kazazian HHJ (2003) Curr Opin Genet Dev 13:651-658.

Table S1. The exaptation of mobile element classes and families

| Repeat | | Exa | pted | Gen | iomic | Genomic/Exapted | |
|---------|------------|--------|---------|---------|-----------|-----------------|--------|
| class | family | blocks | bases | blocks | bases | blocks | bases |
| | CR1 | 2325 | 242446 | 76071 | 13553443 | 32.7 | 55.9 |
| | L2 | 2052 | 192636 | 439841 | 106691082 | 214.3 | 553.8 |
| | L1 | 1389 | 145365 | 662145 | 309380061 | 476.7 | 2128.2 |
| | RTE | 500 | 49763 | 20225 | 4114685 | 40.4 | 82.6 |
| LINE | | 6245 | 629707 | 1187550 | 433565705 | 190.1 | 688.5 |
| | MIR | 3069 | 280215 | 617031 | 96166955 | 201.0 | 343.1 |
| | Alu | 0 | 0 | 5571 | 873110 | - | - |
| SINE | | 3069 | 280215 | 622537 | 97038284 | 202.8 | 346.2 |
| | MER1_type | 315 | 29503 | 194991 | 36545702 | 619.0 | 1238.7 |
| | Mariner | 80 | 8574 | 6507 | 932209 | 81.3 | 108.7 |
| | Tip100 | 50 | 4590 | 25829 | 6122175 | 516.5 | 1333.8 |
| | Tc2 | 45 | 5045 | 7472 | 1634814 | 166.0 | 324.0 |
| | MER2_type | 26 | 2656 | 25491 | 8404638 | 980.4 | 3164.3 |
| | DNA | 21 | 1645 | 13796 | 1858964 | 656.9 | 1130.0 |
| | AcHobo | 20 | 1747 | 18851 | 3538969 | 942.5 | 2025.7 |
| | MER1_type? | 4 | 410 | 4981 | 934050 | 1245.2 | 2278.1 |
| | hAT | 1 | 61 | 3097 | 457999 | 3097.0 | 7508.1 |
| | Merlin | 0 | 0 | 43 | 17994 | - | - |
| | MuDR | 0 | 0 | 1534 | 509074 | - | - |
| | PiggyBac | 0 | 0 | 466 | 182189 | - | - |
| DNA | | 560 | 54227 | 298284 | 60698710 | 532.6 | 1119.3 |
| | MaLR | 231 | 25729 | 219847 | 73836820 | 951.7 | 2869.7 |
| | ERVL | 152 | 16765 | 112297 | 39788552 | 738.7 | 2373.3 |
| | ERV1 | 27 | 2229 | 52186 | 21427661 | 1932.8 | 9613.1 |
| | ERV | 0 | 0 | 531 | 191902 | - | - |
| LTR | | 407 | 44483 | 378055 | 135112875 | 928.8 | 3037.4 |
| Unknown | Unknown | 274 | 34464 | 1048 | 212008 | 3.8 | 6.1 |
| Total | | 10402 | 1035076 | 2355046 | 724110376 | 226.4 | 699.5 |

The hierarchical naming scheme of repeat class, family, and subfamily is as defined by RepeatMasker [2] and Repbase [1]. All pan-boreoeutherian mobile elements are grouped here by class and family. The only Alu family is solely comprised of the "Fossil Alu Monomer" subfamily [11], of which dog has a single copy. The unknown category is solely comprised of the MER121 paralog family. For each repeat grouping we first list the number of instances and total number of bases it has contributed to our set of exapted CNEs. We then list, for comparison, the number and total base pair abundance of instances from that family in the genome. Finally, we divide, per instance and per base, the genomic abundance by the exapted abundance, to obtain a "one in" statistic (e.g., one in every 32.7 CR1 instances in the human genome has been identified as exapted by our survey). If orthologous bases are annotated, for example, as an L1 in one species, but as an L2 in another species, these bases will be added to both the L1 and L2 totals, but will appear only once in the total for all LINEs. Similarly, for contradictory annotation at the class level. This causes some discrepancy between the totals and the breakdown sums they represent.

Table S2. The exaptation of mobile element subfamilies

| Repeat | Repeat Exapted | | Ger | Genomic | | Genomic/Exapted | |
|-----------|----------------|--------|--------|-----------|--------|-----------------|--|
| Name | blocks | bases | blocks | bases | blocks | bases | |
| L2 | 2052 | 192636 | 439841 | 106691082 | 214.3 | 553.8 | |
| MIRb | 1507 | 141220 | 334952 | 52950441 | 222.2 | 374.9 | |
| L3 | 1405 | 152185 | 55672 | 10961735 | 39.6 | 72 | |
| MIR | 1035 | 95799 | 255893 | 40300081 | 247.2 | 420.6 | |
| L3_Mars | 699 | 74807 | 17741 | 2544321 | 25.3 | 34 | |
| L3_iviars | 643 | 68085 | 10465 | 1506385 | 16.2 | 22.1 | |
| L1M5 | | | l | | | 446.7 | |
| - 1 | 604 | 63453 | 95230 | 28344661 | 157.6 | | |
| MIR3 | 579 | 50391 | 86987 | 11397306 | 150.2 | 226.1 | |
| L4 | 500 | 49763 | 20225 | 4114685 | 40.4 | 82.6 | |
| MIR_Mars | 493 | 46250 | 24437 | 3348809 | 49.5 | 72.4 | |
| L1ME4a | 474 | 49721 | 47303 | 11096591 | 99.7 | 223.1 | |
| MIRm | 453 | 38641 | 60444 | 6369153 | 133.4 | 164.8 | |
| MER121 | 274 | 34464 | 1048 | 212008 | 3.8 | 6.1 | |
| L1MC | 179 | 19463 | 28520 | 8005488 | 159.3 | 411.3 | |
| THER1_MD | 177 | 15706 | 27520 | 3322275 | 155.4 | 211.5 | |
| L1MC4a | 148 | 15130 | 35734 | 12424118 | 241.4 | 821.1 | |
| L1ME3B | 92 | 10418 | 31990 | 11982609 | 347.7 | 1150.1 | |
| MARNA | 78 | 8431 | 3693 | 722941 | 47.3 | 85.7 | |
| L1M4 | 74 | 7608 | 30362 | 11855107 | 410.2 | 1558.2 | |
| L1MD | 70 | 7049 | 18100 | 6276365 | 258.5 | 890.3 | |
| L1MC4 | 60 | 7161 | 33392 | 11838631 | 556.5 | 1653.2 | |
| HAL1 | 60 | 5652 | 28567 | 10436160 | 476.1 | 1846.4 | |
| MER5A | 60 | 4903 | 38672 | 5202703 | 644.5 | 1061.1 | |
| HAL1b | 59 | 6171 | 8716 | 2366506 | 147.7 | 383.4 | |
| MLT1K | 58 | 5831 | 20801 | 4960259 | 358.6 | 850.6 | |
| L1MEe | 57 | 5213 | 19253 | 6882233 | 337.7 | 1320.2 | |
| L1MEd | 53 | 5547 | 20897 | 7592323 | 394.2 | 1368.7 | |
| MER5B | 52 | 4592 | 26120 | 3353832 | 502.3 | 730.3 | |
| ERVL-E | 44 | 5051 | 12395 | 6138109 | 281.7 | 1215.2 | |
| MER117 | 44 | 4373 | 4969 | 686551 | 112.9 | 156.9 | |
| Charlie8 | 43 | 3844 | 9520 | 1646050 | 221.3 | 428.2 | |
| L1ME3A | 34 | 3393 | 18730 | 7230802 | 550.8 | 2131 | |
| MLT1I | 32 | 3615 | 12482 | 2842168 | 390 | 786.2 | |
| MER102b | 30 | 3044 | 4868 | 1086097 | 162.2 | 356.7 | |
| L1MEc | 29 | 2931 | 26236 | 13344450 | 904.6 | 4552.8 | |
| LTR67 | 29 | 2846 | 7333 | 1354247 | 252.8 | 475.8 | |
| L1ME2 | 28 | 3262 | 19419 | 8691830 | 693.5 | 2664.5 | |
| MLT1L | 28 | 2771 | 13327 | 2917793 | 475.9 | 1052.9 | |
| L1ME1 | 28 | 2771 | 30950 | 15867176 | 1105.3 | 5814.2 | |
| | | | | | 1 | | |
| L1M | 26 | 3109 | 16353 | 6248253 | 628.9 | 2009.7 | |
| MLT1J | 24 | 2855 | 17227 | 4403127 | 717.7 | 1542.2 | |
| Kanga1 | 24 | 2527 | 3790 | 722004 | 157.9 | 285.7 | |
| MLT1H | 21 | 2747 | 10942 | 3173804 | 521 | 1155.3 | |
| L1M3 | 21 | 2097 | 11962 | 4631475 | 569.6 | 2208.6 | |
| L1MC5 | 20 | 1628 | 21522 | 5957853 | 1076.1 | 3659.6 | |
| MER113 | 18 | 1581 | 4786 | 922878 | 265.8 | 583.7 | |
| L1M2 | 17 | 1948 | 13501 | 9005300 | 794.1 | 4622.8 | |
| LTR33 | 17 | 1589 | 9629 | 2620481 | 566.4 | 1649.1 | |
| MER103 | 17 | 1362 | 7600 | 906315 | 447 | 665.4 | |
| L1MDa | 15 | 1586 | 13316 | 7062585 | 887.7 | 4453 | |

The 50 subfamilies that contributed the most blocks of exapted bases.

Table S3. The exaptation of mobile element subfamilies

| Repeat | Exa | nted | Ger | nomic | Genomic/ | Evanted |
|-----------------------|--------|--------|-------------|-------------------|----------|---------|
| Name | blocks | bases | blocks | bases | blocks | bases |
| | | | | | | |
| MER121 | 274 | 34464 | 1048 | 212008 | 3.8 | 6.1 |
| MER57C2 | 1 | 72 | 16 | 3151 | 16 | 43.7 |
| L3b | 643 | 68085 | 10465 | 1506385 | 16.2 | 22.1 |
| L3_Mars | 699 | 74807 | 17741 | 2544321 | 25.3 | 34 |
| Kanga1c | 5 | 671 | 190 | 76883 | 38 | 114.5 |
| L3 | 1405 | 152185 | 55672 | 10961735 | 39.6 | 72 |
| L4 | 500 | 49763 | 20225 | 4114685 | 40.4 | 82.6 |
| MARNA | 78 | 8431 | 3693 | 722941 | 47.3 | 85.7 |
| MIR ₋ Mars | 493 | 46250 | 24437 | 3348809 | 49.5 | 72.4 |
| Tigger6b | 2 | 324 | 100 | 49159 | 50 | 151.7 |
| Charlie6 | 5 | 369 | 271 | 128113 | 54.2 | 347.1 |
| MER102a | 8 | 756 | 502 | 132643 | 62.7 | 175.4 |
| MER70-int | 3 | 542 | 190 | 75974 | 63.3 | 140.1 |
| Tigger8 | 12 | 1293 | 911 | 228041 | 75.9 | 176.3 |
| MER45R | 3 | 270 | 265 | 140864 | 88.3 | 521.7 |
| MER99 | 3 | 229 | 277 | 98883 | 92.3 | 431.8 |
| LTR58 | 1 | 50 | 95 | 32441 | 95 | 648.8 |
| L1ME4a | 474 | 49721 | 47303 | 11096591 | 99.7 | 223.1 |
| Kanga2_a | 14 | 1484 | 1472 | 433115 | 105.1 | 291.8 |
| Charlie11 | 1 | 58 | 109 | 39126 | 109 | 674.5 |
| MER117 | 44 | 4373 | 4969 | 686551 | 112.9 | 156.9 |
| MLT1H2-int | 1 | 147 | 116 | 115671 | 116 | 786.8 |
| FordPrefect | 4 | 464 | 471 | 271573 | 117.7 | 585.2 |
| LTR68 | 3 | 226 | 369 | 110614 | 123 | 489.4 |
| MIRm | 453 | 38641 | 60444 | 6369153 | 133.4 | 164.8 |
| LTR69 | 1 | 50 | 140 | 54630 | 140 | 1092.6 |
| HAL1b | 59 | 6171 | 8716 | 2366506 | 147.7 | 383.4 |
| MIR3 | 579 | 50391 | 86987 | 11397306 | 150.2 | 226.1 |
| LTR52-int | 2 | 318 | 302 | 151329 | 151 | 475.8 |
| THER1_MD | 177 | 15706 | 27520 | 3322275 | 155.4 | 211.5 |
| L1M5 | 604 | 63453 | 95230 | 28344661 | 157.6 | 446.7 |
| Kanga1 | 24 | 2527 | 3790 | 722004 | 157.0 | 285.7 |
| L1MC | 179 | 19463 | 28520 | 8005488 | 157.9 | 411.3 |
| MER102b | 30 | 3044 | | | 162.2 | 356.7 |
| MER102B | 3 | 270 | 4868 511 | 1086097 273651 | 170.3 | 1013.5 |
| | 5 | | 1 | | 1 | 492.7 |
| Zaphod2 | 1 | 336 | 871 | 165551 | 174.2 | |
| L1M2a1 ERVL | 11 | 63 | 179 | 176275 | 179 | 2798 |
| | 1 | 1176 | 2028 | 843493 | 184.3 | 717.2 |
| L2 | 2052 | 192636 | 439841 | 106691082 | 214.3 | 553.8 |
| Charlie8 | 43 | 3844 | 9520 | 1646050 | 221.3 | 428.2 |
| MIRb | 1507 | 141220 | 334952 | 52950441 | 222.2 | 374.9 |
| MER51-int | 1 1 | 101 | 224 | 136231 | 224 | 1348.8 |
| MER91B | 7 | 438 | 1581 | 181805 | 225.8 | 415 |
| MER97b | 1 | 151 | 239 | 76827 | 239 | 508.7 |
| L1MC4a | 148 | 15130 | 35734 | 12424118 | 241.4 | 821.1 |
| LTR65 | 2 | 201 | 484 | 130221 | 242 | 647.8 |
| MIR | 1035 | 95799 | 255893 | 40300081 | 247.2 | 420.6 |
| Charlie4 | 8 | 1180 | 1999 | 293395 | 249.8 | 248.6 |
| LTR67 | 29 | 2846 | 7333 | 1354247 | 252.8 | 475.8 |
| L1MD | 70 | 7049 | 18100 | 6276365 | 258.5 | 890.3 |

The 50 subfamilies that have the most impressive ratios of genomic blocks to exapted blocks.

Top GO enrichment p-values for the set of all exapted regions using a uniform null distribution

transcription regulator activity and related terms
development and related terms
cell adhesion and related terms

p-value GO term

| | GO term |
|---|---|
| 1.84E-75 | development |
| 1.09E-72 | transcription regulator activity |
| 5.45E-58 | transcription factor activity |
| 3.52E-55 | system development |
| 3.12E-53 | nervous system development |
| 9.19E-53 | regulation of cellular metabolism |
| 3.73E-52 | regulation of transcription, DNA-dependent |
| 9.89E-51 | DNA binding |
| 1.17E-50 | transcription, DNA-dependent |
| 1.76E-50 | regulation of metabolism |
| 2.03E-50 | binding |
| 8.56E-49 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| 1.41E-48 | regulation of transcription |
| 2.92E-46 | transcription |
| | regulation of cellular physiological process |
| 4.43E-42 | regulation of physiological process |
| 4.71E-40 | regulation of biological process |
| 1.76E-39 | nucleic acid binding |
| | sequence-specific DNA binding |
| | regulation of cellular process |
| | organ development |
| | cell differentiation |
| | nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| 9.98E-27 | |
| | transcription from RNA polymerase II promoter |
| 1.08E-25 | |
| 1.22E-25 | · |
| | protein binding |
| | transcription factor binding |
| | cell recognition |
| | transmembrane receptor protein tyrosine kinase signaling pathway |
| | neuron recognition |
| | GPI anchor binding |
| 5.65E-21 | enzyme linked receptor protein signaling pathway |
| | |
| | skeletal development |
| 1.17E-19 | skeletal development cellular process |
| 1.17E-19 1.45E-19 | skeletal development cellular process phosphoinositide binding |
| 1.17E-19 1.45E-19 2.05E-19 | skeletal development cellular process phosphoinositide binding cell development |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 | skeletal development cellular process phosphoinositide binding cell development morphogenesis |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 3.34E-17 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 3.34E-17 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 3.34E-17 1.28E-16 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 3.34E-17 1.28E-16 1.32E-16 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 3.34E-17 1.28E-16 1.67E-16 2.34E-16 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 3.34E-17 1.28E-16 1.32E-16 2.34E-16 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 7.26E-16 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 3.34E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 7.26E-16 2.58E-15 3.82E-15 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 3.42E-15 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 3.46E-15 5.40E-15 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 3.34E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 3.42E-15 5.40E-15 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 4.20E-15 5.40E-15 5.78E-15 6.17E-15 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation neurogenesis |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 5.40E-15 5.78E-15 9.22E-15 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation neurogenesis cell glucose homeostasis |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.34E-15 3.46E-15 3.46E-15 5.40E-15 5.78E-15 6.17E-15 9.22E-15 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation neurogenesis cell glucose homeostasis RNA-mediated gene silencing |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.34E-15 3.46E-15 3.46E-15 5.78E-15 6.17E-15 9.22E-14 1.22E-14 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation neurogenesis cell glucose homeostasis RNA-mediated gene silencing RNA-mediated posttranscriptional gene silencing |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.34E-15 3.82E-15 3.82E-15 5.40E-15 5.78E-15 6.17E-15 9.22E-14 1.22E-14 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation neurogenesis cell glucose homeostasis RNA-mediated gene silencing RNA-mediated posttranscriptional gene silencing posttranscriptional gene silencing |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 3.46E-15 5.78E-15 6.17E-15 9.22E-15 1.22E-14 1.22E-14 2.06E-14 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation neurogenesis cell glucose homeostasis RNA-mediated gene silencing posttranscriptional gene silencing phospholipid binding |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 5.40E-15 5.78E-15 6.17E-15 9.22E-15 1.22E-14 1.22E-14 2.06E-14 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation neurogenesis cell glucose homeostasis RNA-mediated gene silencing phospholipid binding negative regulation of development |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 3.46E-15 5.40E-15 5.78E-15 6.17E-16 9.22E-14 1.22E-14 1.22E-14 2.06E-14 2.23E-14 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation neurogenesis cell glucose homeostasis RNA-mediated gene silencing posttranscriptional gene silencing posttranscriptional gene silencing phospholipid binding negative regulation of development cell adhesion |
| 1.17E-19 1.45E-19 2.05E-19 4.07E-19 6.46E-18 8.35E-18 1.12E-17 1.28E-16 1.32E-16 2.34E-16 2.34E-16 2.58E-15 3.46E-15 5.40E-15 5.78E-15 6.17E-15 9.22E-14 1.22E-14 1.22E-14 2.23E-14 2.51E-14 3.81E-14 | skeletal development cellular process phosphoinositide binding cell development morphogenesis embryonic development hemopoiesis hemopoietic or lymphoid organ development transcription cofactor activity transmembrane receptor protein kinase activity transmembrane receptor protein tyrosine kinase activity neuron differentiation BRE binding translation repressor activity, nucleic acid binding RNA polymerase II transcription factor activity central nervous system development translation repressor activity neuron development osteoblast differentiation RNA interference negative regulation of cell differentiation neurogenesis cell glucose homeostasis RNA-mediated gene silencing phospholipid binding negative regulation of development |

Table S4. Most significant p-values for all exapted elements when a uniform null over bases in the genome is used. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for the set of all exapted regions using a uniform null distribution where each gene can only be selected once transcription regulator activity and related terms development and related terms cell adhesion and related terms

| p-value | GO term |
|----------|---|
| | development |
| | system development |
| | nervous system development |
| | transcription regulator activity |
| | transcription factor activity |
| | sequence-specific DNA binding |
| | organ development |
| | cell adhesion |
| | |
| | enzyme linked receptor protein signaling pathway central nervous system development |
| | ion channel activity |
| | |
| | channel or pore class transporter activity |
| | alpha-type channel activity |
| | cation channel activity |
| 1.65E-08 | |
| | voltage-gated ion channel activity |
| | skeletal development |
| | transmembrane receptor protein tyrosine kinase signaling pathway |
| | cell-cell adhesion |
| | morphogenesis |
| | metal ion transport |
| | calcium ion binding |
| | cell communication |
| | plasma membrane part |
| | potassium channel activity |
| 5.02E-07 | |
| | protein binding |
| | transmembrane receptor protein kinase activity |
| | plasma membrane |
| | transcription from RNA polymerase II promoter |
| | regulation of biological process |
| | voltage-gated potassium channel activity |
| | calcium ion transport |
| | regulation of transcription, DNA-dependent |
| | potassium ion transport |
| | regulation of transcription |
| | brain development |
| | voltage-gated potassium channel complex |
| | intrinsic to plasma membrane |
| | cation transport |
| | transcription, DNA-dependent |
| | signal transduction |
| | homophilic cell adhesion |
| | integral to plasma membrane |
| | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| | neurogenesis |
| | regulation of cellular process |
| | ion transporter activity |
| | neuron differentiation |
| 1.22E-05 | extracellular matrix part |
| | extracellular matrix |
| 1.38E-05 | ion transport |
| 1.47E-05 | glutamate receptor activity |
| 1.48E-05 | transcription |
| 2.02E-05 | cation transporter activity |
| | embryonic development |
| 2.64E-05 | DNA binding |
| 2.75E-05 | regulation of physiological process |
| 2.92E-05 | glutamate-gated ion channel activity |
| 2.92E-05 | ionotropic glutamate receptor activity |
| | regulation of cellular metabolism |
| | cell differentiation |
| | transmembrane receptor protein tyrosine kinase activity |
| | membrane |
| | cellular morphogenesis |
| | |

Table S5. Most significant p-values for all exapted elements when a uniform null over genes in the genome is used and each gene can only be selected once. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for the set of all exapted regions using the location of all repeat insertions as the null distribution

transcription regulator activity and related terms
development and related terms
cell adhesion and related terms

p-value GO term 2.24E-64 transcription regulator activity 2.33E-60 development 3.47E-51 transcription factor activity 8.37E-48 regulation of cellular metabolism 9.86E-48 DNA binding 1.48E-47 regulation of transcription, DNA-dependent 5.19E-46 transcription, DNA-dependent 1.31E-45 regulation of metabolism 3.81E-45 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 3.87E-45 system development 8.27E-45 regulation of transcription 2.11E-43 nervous system development 1.58E-42 transcription 2.01E-37 nucleic acid binding 3.69E-37 sequence-specific DNA binding 1.34E-35 regulation of cellular physiological process 3.39E-34 binding 4.16E-34 regulation of physiological process 1.42E-31 regulation of biological process 1.26E-30 regulation of cellular process 2.47E-30 nucleobase, nucleoside, nucleotide and nucleic acid metabolism 4.70E-29 cell differentiation 8.64E-29 organ development 4.28E-25 nucleus 3.78E-22 transcription from RNA polymerase II promoter 1.13E-21 GPI anchor binding 5.08E-21 cell recognition 2.62E-20 neuron recognition 1.15E-19 transcription factor binding 5.10E-19 phosphoinositide binding 8.27E-18 transmembrane receptor protein tyrosine kinase signaling pathway 1.08E-16 cell development 3.51E-16 enzyme linked receptor protein signaling pathway 3.80E-16 BRE binding 3.80E-16 translation repressor activity, nucleic acid binding 8.45E-16 hemopoiesis 1.14E-15 hemopoietic or lymphoid organ development 1.37E-15 cell adhesion 2.33E-15 translation repressor activity 5.94E-15 cell 6.34E-15 cell part 7.32E-15 skeletal development 8.15E-15 transmembrane receptor protein kinase activity 8.19E-15 protein binding 9.58E-15 transmembrane receptor protein tyrosine kinase activity 1.06E-14 transcription cofactor activity 2.84E-14 RNA interference 4.05E-14 morphogenesis 4.06E-14 embryonic development 4.31E-14 phospholipid binding 5.82E-14 RNA-mediated gene silencing 5.82E-14 RNA-mediated posttranscriptional gene silencing 5.82E-14 posttranscriptional gene silencing 6.95E-14 RNA polymerase II transcription factor activity 2.23E-13 neuron differentiation 3.31E-13 cell-cell adhesion 6.15E-13 neuron development 6.20E-13 cell glucose homeostasis 5.14E-12 neurogenesis 6.70E-12 osteoblast differentiation 8.78E-12 response to starvation 1.00E-11 gene silencing 1.32E-11 brown fat cell differentiation 1.32E-11 positive regulation of histone acetylation 1.38E-11 germ cell development

Table S6. Most significant p-values for all exapted elements when the distribution of all mobile elements in the genome is used as the null distribution. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for classes of exapted regions using a uniform null distribution

using a uniform null distribution
transcription regulator activity and related terms
development and related terms
cell adhesion and related terms

| class | p-value | GO term |
|--|----------------------|--|
| LINE | 7.77E-43 | transcription regulator activity |
| LINE | 3.90E-36 | development |
| LINE | 1.91E-34 | transcription factor activity |
| LINE | 2.48E-34 | system development |
| LINE | 1.12E-33 | nervous system development |
| LINE | 1.99E-30 | DNA binding |
| LINE | 3.58E-30 | regulation of transcription, DNA-dependent |
| LINE | 4.64E-30 | regulation of cellular metabolism |
| SINE | 2.50E-29 | development |
| LINE | 2.63E-29 | transcription, DNA-dependent |
| LINE | 5.58E-29 | regulation of metabolism |
| LINE | 1.15E-28 | regulation of transcription |
| LINE | 1.67E-28 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| LINE | 3.27E-27 | transcription |
| LINE | 1.15E-25 | binding |
| SINE | 3.04E-24 | transcription regulator activity |
| LINE | 1.00E-22 | regulation of cellular physiological process |
| LINE | 3.89E-22 | sequence-specific DNA binding |
| LINE | 4.69E-22 | cell |
| LINE | 4.85E-22 | cell part |
| LINE | 4.90E-22 | regulation of physiological process |
| LINE | 5.16E-22 | nucleic acid binding |
| SINE | 1.22E-20 | regulation of cellular metabolism |
| SINE | 2.19E-20 | transcription factor activity |
| SINE | 3.49E-20 | binding |
| LINE | 3.69E-20 | organ development |
| SINE | 1.82E-19 | regulation of metabolism |
| LINE | 1.96E-19 | regulation of biological process |
| SINE | 4.41E-19 | regulation of transcription, DNA-dependent |
| LINE | 6.80E-19 | regulation of cellular process |
| LINE | 9.71E-19 | transmembrane receptor protein tyrosine kinase signaling pathway |
| SINE | 1.06E-18 | transcription, DNA-dependent |
| SINE | 1.49E-18 | DNA binding |
| SINE | 1.52E-18 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| SINE | 6.62E-18 | regulation of transcription |
| LINE | 9.16E-18 | cell differentiation |
| LINE | 1.45E-17 | nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| SINE | 2.73E-17 | transcription |
| SINE | 2.75E-17 | nucleic acid binding |
| SINE | 4.61E-17 | regulation of physiological process |
| LINE | 4.68E-17 | enzyme linked receptor protein signaling pathway |
| LINE | 5.81E-17 | nucleus |
| SINE | 6.14E-17 | regulation of cellular physiological process |
| LINE | 7.08E-17 | cell recognition |
| SINE | 7.60E-17 | regulation of biological process |
| LINE | 2.88E-16 | GPI anchor binding |
| SINE | 1.12E-15 | system development |
| SINE | 1.76E-15 | regulation of cellular process |
| LINE | 2.22E-15 | transmembrane receptor protein tyrosine kinase activity |
| SINE | 4.52E-15 | nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| SINE | 1.70E-14 | nervous system development |
| LINE | 2.26E-14 | neuron recognition |
| LINE | 2.47E-14 | transmembrane receptor protein kinase activity |
| SINE | 3.04E-14 | sequence-specific DNA binding |
| LINE | 4.33E-14 | transcription from RNA polymerase II promoter |
| LINE | 1.61E-13 | phosphoinositide binding |
| Unknown | 1.77E-13 | development |
| SINE | 1.94E-13 | hemopoiesis |
| SINE | 2.24E-13 | hemopoietic or lymphoid organ development |
| LINE | 6.06E-13 | transcription factor binding |
| SINE | 6.57E-13 | cell differentiation |
| LINE | 8.72E-13 | protein binding |
| SINE | | protein binding organ development |
| | 1.53E-12 3.38E-12 | organ development embryonic development |
| 1 > 11 \text{\ti}\text{\tin\tint{\text{\ti}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\tint{\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\tin}\tittt{\text{\text{\text{\text{\text{\texi}\titt{\text{\ti}\tittt{\text{\text{\text{\texi}\tittitt{\text{\texi}\tittitt{\titil\titt{\text{\ti}\tint{\tiint{\text{\tii}\tittt{\tint}\ | | CITIDI VOLIIC GEVEIUDITICITI |
| SINE SINE | 8.83E-12 | transcription from RNA polymerase II promoter |

Table S7. Most significant p-values for classes of exapted elements when a uniform null over bases in the genome is used. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for classes of exapted regions using a uniform null distribution where each gene can only be selected once transcription regulator activity and related terms development and related terms cell adhesion and related terms class p-value GO term SINE 1.76E-20 development LINE 1.79E-20 system development LINE 1.93E-20 transcription regulator activity LINE 4.11E-20 development LINE 6.30E-20 nervous system development LINE 3.95E-18 transcription factor activity SINE 8.30E-18 system development SINE 3.87E-17 nervous system development SINE 3.58E-15 transcription factor activity 1.15E-14 transcription regulator activity SINE LINE 1.52E-14 sequence-specific DNA binding 6.50E-14 sequence-specific DNA binding SINE LINE 1.05E-13 organ development Unknown 1.73E-12 development LINE 2.06E-11 cell adhesion 3.41E-10 enzyme linked receptor protein signaling pathway LINE Unknown 8.74E-10 organ development 1.76E-09 central nervous system development LINE Unknown 3.18E-09 transcription factor activity DNA 3.30E-09 development 5.12E-09 protein binding LINE DNA 6.58E-09 nervous system development SINE 7.15E-09 cell-cell adhesion DNA 7.97E-09 system development LTR 1.13E-08 development 1.58E-08 central nervous system development SINE LINE 2.21E-08 transmembrane receptor protein kinase activity LINE 2.61E-08 regulation of transcription, DNA-dependent Unknown 3.68E-08 transcription regulator activity LINE 3.74E-08 regulation of transcription LINE 4.46E-08 transmembrane receptor protein tyrosine kinase signaling pathway SINE 4.61E-08 cell adhesion LINE 6.16E-08 synapse 7.41E-08 organ development LTR SINF 9.49E-08 organ development LINE 1.04E-07 cell-cell adhesion 1.25E-07 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism LINE SINE 1.45E-07 ion channel activity 1.71E-07 transcription, DNA-dependent binding INE SINE SINE 2.79E-07 homophilic cell adhesion SINE 3.49E-07 morphogenesis 3.70E-07 alpha-type channel activity SINE 4.37E-07 calcium ion binding SINE SINE 4.40E-07 channel or pore class transporter activity SINE 4.78E-07 cell communication LINE 4.96E-07 regulation of biological process 4.98E-07 cell differentiation Unknown LINE 5.59E-07 transcription 6.68E-07 sequence-specific DNA binding Unknown 7.76E-07 regulation of cellular metabolism LINE 9.64E-07 brain development SINE 1.19E-06 skeletal development LINE SINE 1.30E-06 transcription from RNA polymerase II promoter regulation of transcription, DNA-dependent SINE 1.43E-06 1.49E-06 regulation of biological process SINE SINE 1.62E-06 cation channel activity LINE 1.63E-06 ionotropic glutamate receptor activity 1.63E-06 glutamate-gated ion channel activity LINE LINE 1.72E-06 transmembrane receptor protein tyrosine kinase activity 1.76E-06 cell differentiation LINE LTR 1.79E-06 homophilic cell adhesion 1.91E-06 membrane LINE 1.96E-06 morphogenesis INF SINE 1.98E-06 DNA binding

Table S8. Most significant p-values for classes of exapted elements when a uniform null over genes is used and each gene can only be selected once. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for classes of exapted regions using the location of all repeat insertions as the null distribution transcription regulator activity and related terms development and related terms cell adhesion and related terms

| | | cell adhesion and related terms |
|--|--|---|
| class | p-value | |
| LINE | 7.82E-41 | - ' ' |
| LINE | | transcription factor activity |
| LINE | | development |
| LINE | | system development |
| LINE | | nervous system development |
| LINE | | regulation of transcription, DNA-dependent |
| LINE | | DNA binding |
| LINE | | regulation of cellular metabolism |
| LINE | | transcription, DNA-dependent |
| LINE | | regulation of transcription |
| LINE | 2.85E-26 | , , |
| LINE | | regulation of metabolism |
| LINE | | transcription |
| LINE | | sequence-specific DNA binding |
| LINE | 3.25E-19 | regulation of cellular physiological process |
| LINE | | nucleic acid binding |
| LINE | 2.54E-18 | |
| LINE | | regulation of physiological process |
| LINE | 6.20E-18 | GPI anchor binding |
| LINE | 2.51E-17 | cell differentiation |
| LINE | 5.22E-17 | |
| LINE | 9.60E-17 | |
| LINE | 2.41E-16 | |
| SINE | | development |
| LINE | | regulation of cellular process |
| SINE | | nucleic acid binding |
| LINE | | nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| LINE | 9.15E-16 | regulation of biological process |
| SINE | 3.07E-15 | DNA binding |
| SINE | 5.02E-15 | |
| LINE | 6.79E-15 | neuron recognition |
| LINE | 1.12E-14 | enzyme linked receptor protein signaling pathway |
| LINE | 1.89E-14 | cell part |
| LINE | 1.92E-14 | _cell |
| SINE | 2.22E-14 | transcription regulator activity |
| SINE | 2.93E-14 | regulation of metabolism |
| LINE | 4.57E-14 | transmembrane receptor protein tyrosine kinase activity |
| LINE | 4.71E-14 | phosphoinositide binding |
| SINE | 5.58E-14 | regulation of transcription, DNA-dependent |
| LINE | 5.97E-14 | nucleus |
| SINE | 9.46E-14 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| SINE | 1.15E-13 | transcription, DNA-dependent |
| LINE | 2.79E-13 | transmembrane receptor protein kinase activity |
| SINE | 4.44E-13 | regulation of transcription |
| LINE | 8.75E-13 | transcription from RNA polymerase II promoter |
| SINE | 1.31E-12 | transcription |
| SINE | 2.71E-12 | nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| SINE | | transcription factor activity |
| SINE | 2.55E-11 | binding |
| LINE | 4.76E-11 | cell adhesion |
| LINE | 5.30E-11 | |
| LINE | 5.78E-11 | transcription factor binding |
| SINE | | |
| | 6.07E-11 | regulation of cellular physiological process |
| LINE | 6.07E-11 1.06E-10 | RNA polymerase II transcription factor activity |
| LINE SINE | | |
| | 1.06E-10 | RNA polymerase II transcription factor activity |
| SINE | 1.06E-10 1.49E-10 | RNA polymerase II transcription factor activity regulation of physiological process |
| SINE LINE | 1.06E-10 1.49E-10 1.58E-10 | RNA polymerase II transcription factor activity regulation of physiological process phospholipid binding |
| SINE LINE LINE | 1.06E-10 1.49E-10 1.58E-10 2.53E-10 | RNA polymerase II transcription factor activity regulation of physiological process phospholipid binding cell development |
| SINE LINE LINE SINE | 1.06E-10 1.49E-10 1.58E-10 2.53E-10 2.66E-10 | RNA polymerase II transcription factor activity regulation of physiological process phospholipid binding cell development sequence-specific DNA binding |
| SINE LINE LINE SINE LINE | 1.06E-10 1.49E-10 1.58E-10 2.53E-10 2.66E-10 4.78E-10 | RNA polymerase II transcription factor activity regulation of physiological process phospholipid binding cell development sequence-specific DNA binding gene silencing |
| SINE LINE LINE SINE LINE SINE | 1.06E-10 1.49E-10 1.58E-10 2.53E-10 2.66E-10 4.78E-10 6.26E-10 | RNA polymerase II transcription factor activity regulation of physiological process phospholipid binding cell development sequence-specific DNA binding qene silencing regulation of biological process |
| SINE LINE SINE LINE SINE SINE SINE | 1.06E-10 1.49E-10 1.58E-10 2.53E-10 2.66E-10 4.78E-10 6.26E-10 7.80E-10 | RNA polymerase II transcription factor activity regulation of physiological process phospholipid binding cell development sequence-specific DNA binding qene silencing regulation of biological process hemopoiesis |
| SINE LINE SINE LINE SINE SINE SINE SINE | 1.06E-10 1.49E-10 1.58E-10 2.53E-10 2.66E-10 4.78E-10 6.26E-10 7.80E-10 9.37E-10 | RNA polymerase II transcription factor activity regulation of physiological process phospholipid binding cell development sequence-specific DNA binding gene silencing regulation of biological process hemopoiesis hemopoietic or lymphoid organ development |

Table S9. Most significant p-values for classes of exapted elements when the distribution of all mobile elements in the genome is used as the null distribution. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for families of exapted regions using a uniform null distribution

transcription regulator activity and related terms
development and related terms
cell adhesion and related terms

| family | p-value | GO term |
|----------------|----------------------|---|
| MIR | 2.50E-29 | |
| MIR | 3.04E-24 | transcription regulator activity |
| MIR | 1.22E-20 | , · · · · · · · · · · · · · · · · · · · |
| MIR | 2.19E-20 | transcription factor activity |
| MIR | 3.49E-20 | binding |
| MIR | 1.82E-19 | regulation of metabolism |
| MIR | 4.41E-19 | regulation of transcription, DNA-dependent |
| MIR | 1.06E-18 | transcription, DNA-dependent |
| MIR | 1.49E-18 | DNA binding |
| MIR | 1.52E-18 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| MIR | 6.62E-18 | regulation of transcription |
| L2 | 9.46E-18 | development |
| MIR | 2.73E-17 | transcription |
| MIR | 2.75E-17 | nucleic acid binding |
| MIR | 4.61E-17 | regulation of physiological process |
| CR1 | 5.36E-17 | transcription regulator activity |
| MIR | 6.14E-17 | regulation of cellular physiological process |
| MIR | 7.60E-17 | regulation of biological process |
| CR1 | 1.80E-16 | |
| MIR | 1.12E-15 | system development |
| CR1 | | transcription factor activity |
| MIR | 1.76E-15 | regulation of cellular process |
| MIR L2 | | nucleobase, nucleoside, nucleotide and nucleic acid metabolism system development |
| MIR | 1 | |
| CR1 | 2.26E-14 | nervous system development sequence-specific DNA binding |
| L2 | + | nervous system development |
| MIR | | sequence-specific DNA binding |
| CR1 | 1 | system development |
| Unknown | | development |
| MIR | | hemopoiesis |
| MIR | 1 | hemopoietic or lymphoid organ development |
| CR1 | 2.65E-13 | nervous system development |
| MIR | 6.57E-13 | cell differentiation |
| L1 | 1.00E-12 | transcription regulator activity |
| MIR | 1.53E-12 | organ development |
| CR1 | 1.57E-12 | DNA binding |
| MIR | 3.38E-12 | · |
| CR1 | 6.53E-12 | binding |
| MIR | 8.83E-12 | transcription from RNA polymerase II promoter |
| L2 | 1.17E-11 | transcription regulator activity |
| L1 | 3.61E-11 | regulation of transcription, DNA-dependent |
| L1 | 4.02E-11 | transcription, DNA-dependent |
| CR1 | 4.92E-11 | regulation of transcription, DNA-dependent |
| CR1 L2 | 5.74E-11 | transmembrane receptor protein tyrosine kinase activity |
| L2 L1 | 6.27E-11 8.02E-11 | transcription factor activity regulation of cellular metabolism |
| L1 L1 | | regulation of ceilular metabolism |
| CR1 | | transcription, DNA-dependent |
| CR1 | | regulation of cellular metabolism |
| L2 | 1.57E-10 | DNA binding |
| CR1 | 1.60E-10 | |
| CR1 | + | regulation of transcription |
| L1 | | transcription |
| L1 | 1.84E-10 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| L1 | 1.88E-10 | |
| CR1 | 2.19E-10 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| MIR | 2.77E-10 | protein binding |
| L1 | 3.70E-10 | transmembrane receptor protein tyrosine kinase signaling pathway |
| CR1 | 3.97E-10 | regulation of metabolism |
| CR1 | 4.19E-10 | nucleic acid binding |
| MIR | 5.14E-10 | nucleus |
| L1 | 7.89E-10 | binding |
| | IO 00F 10 | osteoblast differentiation |
| MIR Unknown | 8.02E-10 8.32E-10 | organ development |

Table \$10. Most significant p-values for families of exapted elements when a uniform null over bases in the genome is used. For an explanation of all GO tests see the Supplemental Text S2.

Top GO enrichment p-values for families of exapted regions using a uniform null distribution where each gene can only be selected once transcription regulator activity and related terms

development and related terms cell adhesion and related terms family p-value GO term MIR 1.76E-20 development 1.88E-20 system development L2 1.22E-19 nervous system development CR1 7.40E-18 development MIR 8.30E-18 system development MIR 3.87E-17 nervous system development L2 CR1 8.95E-16 development 1.40E-15 system development CR1 2.59E-15 nervous system development MIR 3.58E-15 transcription factor activity MIR 1.15E-14 transcription regulator activity 6.50E-14 sequence-specific DNA binding MIR 1.41E-13 transcription regulator activity L1 CR1 5.74E-13 transcription regulator activity Unknown 1.73E-12 development 4.09E-12 nervous system development 11 CR1 5.41E-12 sequence-specific DNA binding 5.63E-12 system development L1 L2 1.66E-11 transcription regulator activity 1.86E-11 transcription factor activity L1 L2 1.96E-11 transcription factor activity CR1 2.48E-11 transcription factor activity CR1 3.35E-10 organ development 3.61E-10 cell adhesion CR1 Unknown 8.74E-10 organ development Unknown 3.18E-09 transcription factor activity 4.35E-09 cell differentiation CR1 MIR 7.15E-09 cell-cell adhesion 1.29E-08 organ development L1 MIR 1.58E-08 central nervous system development 1.85E-08 sequence-specific DNA binding L2 12 2.17E-08 central nervous system development L1 2.75E-08 cell adhesion Unknown 3.68E-08 transcription regulator activity 4.28E-08 cell-cell adhesion L1 MIR 4.61E-08 cell adhesion 6.05E-08 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism L1 6.19E-08 regulation of cellular metabolism L1 CR1 6.86E-08 transmembrane receptor protein kinase activity 6.87E-08 development 11 L1 6.97E-08 regulation of transcription, DNA-dependent 7.54E-08 regulation of transcription L1 8.85E-08 neuron differentiation L2 MIR 9.49E-08 organ development CR1 9.64E-08 cell-cell adhesion L1 9.83E-08 transcription, DNA-dependent L1 9.88E-08 transcription RTE 1.17E-07 transcription regulator activity L1 1.35E-07 sequence-specific DNA binding 1.44E-07 organ development L2 MIR 1.45E-07 ion channel activity MIR 1.80E-07 binding CR1 1.96E-07 transmembrane receptor protein tyrosine kinase activity MIR 2.79E-07 homophilic cell adhesion 2.81E-07 regulation of metabolism L1 3.31E-07 enzyme linked receptor protein signaling pathway L1 MIR 3.49E-07 morphogenesis MIR 3.70E-07 alpha-type channel activity L2 3.81E-07 neurogenesis CR1 3.88E-07 homophilic cell adhesion 4.37E-07 calcium ion binding
4.40E-07 channel or pore class transporter activity MIR MIR MIR 4.78E-07 cell communication CR1 4.88E-07 cell Unknown 4.98E-07 cell differentiation

Table S11. Most significant p-values for families of exapted elements when a uniform null over genes is used and each gene can only be selected once. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for families of exapted regions using the location of all repeat insertions as the null distribution transcription regulator activity and related terms development and related terms cell adhesion and related terms

| family | p-value | cell adhesion and related terms GO term |
|--|--|--|
| MIR | | nucleic acid binding |
| MIR | | development |
| MIR | | DNA binding |
| MIR | | regulation of cellular metabolism |
| MIR | | transcription regulator activity |
| MIR | | regulation of metabolism |
| MIR | | regulation of transcription, DNA-dependent |
| MIR | | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| MIR | | transcription, DNA-dependent |
| L1 | | transcription regulator activity |
| MIR | | regulation of transcription |
| CR1 | | transcription regulator activity |
| MIR | | transcription |
| MIR | | nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| L1 | | nervous system development |
| MIR | | transcription factor activity |
| CR1 | | regulation of transcription, DNA-dependent |
| CR1 | | DNA binding |
| L1 | | system development |
| CR1 | | sequence-specific DNA binding |
| CR1 | 1.30E-11 | |
| L2 | | development |
| MIR | 2.09E-11 | • |
| CR1 | | regulation of transcription |
| CR1 | | transcription factor activity |
| CR1 | | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| CR1 | | regulation of cellular metabolism |
| CR1 | | nucleic acid binding |
| MIR | | regulation of cellular physiological process |
| CR1 | | transcription |
| CR1 | | nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| L2 | | system development |
| MIR | | regulation of physiological process |
| CR1 | | regulation of metabolism |
| L1 | | regulation of transcription, DNA-dependent |
| MIR | | sequence-specific DNA binding |
| L1 | | transcription, DNA-dependent |
| L2 | | nervous system development |
| MIR | | regulation of biological process |
| L1 | | regulation of cellular metabolism |
| MIR | | hemopoiesis |
| L2 | 9.17E-10 | · |
| MIR | 1.07E-09 | - |
| L1 | 1.07E-09 | |
| L1 L1 | 1.20E-09 1.37E-09 | |
| L1 L2 | | transcription regulator activity |
| L2 L1 | 1.73E-09 | |
| L1 L1 | 1.76E-09 | |
| L I MIR | | regulation of transcription |
| L1 | | transcription |
| L1 L1 | 2.29E-09 2.92E-09 | transmembrane receptor protein tyrosine kinase signaling pathway |
| | 2.96E-09 | enzyme linked receptor protein signaling pathway |
| 1 1 | | CHEVING HINCU ICCCDIOI DIOICHI SIGNAHAHA DAHIWAY |
| | | |
| MIR | 5.64E-09 | system development |
| MIR L2 | 5.64E-09 7.09E-09 | system development transcription factor activity |
| MIR L2 MIR | 5.64E-09 7.09E-09 7.69E-09 | system development transcription factor activity embryonic development |
| MIR L2 MIR MIR | 5.64E-09 7.09E-09 7.69E-09 7.94E-09 | system development transcription factor activity embryonic development nucleus |
| MIR L2 MIR MIR MIR | 5.64E-09 7.09E-09 7.69E-09 7.94E-09 1.75E-08 | system development transcription factor activity embryonic development nucleus cell-cell adhesion |
| MIR L2 MIR MIR MIR L1 | 5.64E-09 7.09E-09 7.69E-09 7.94E-09 1.75E-08 2.52E-08 | system development transcription factor activity embryonic development nucleus cell-cell adhesion cell part |
| MIR L2 MIR MIR MIR L1 CR1 | 5.64E-09 7.09E-09 7.69E-09 7.94E-09 1.75E-08 2.52E-08 2.69E-08 | system development transcription factor activity embryonic development nucleus cell-cell adhesion cell part development |
| MIR L2 MIR MIR MIR L1 CR1 | 5.64E-09 7.09E-09 7.69E-09 7.94E-09 1.75E-08 2.52E-08 2.69E-08 2.76E-08 | system development transcription factor activity embryonic development nucleus cell-cell adhesion cell part development cell |
| MIR L2 MIR MIR MIR CR1 L1 L1 L2 | 5.64E-09 7.09E-09 7.69E-09 7.94E-09 1.75E-08 2.52E-08 2.69E-08 2.76E-08 2.92E-08 | system development transcription factor activity embryonic development nucleus cell-cell adhesion cell part development cell regulation of transcription, DNA-dependent |
| MIR L2 MIR MIR MIR L1 CR1 L1 L2 MIR | 5.64E-09 7.09E-09 7.69E-09 7.94E-09 1.75E-08 2.52E-08 2.69E-08 2.76E-08 2.92E-08 3.96E-08 | system development transcription factor activity embryonic development nucleus cell-cell adhesion cell part development cell regulation of transcription, DNA-dependent nervous system development |
| L1 MIR L2 MIR MIR MIR MIR L1 CR1 L1 L2 MIR L2 MIR L2 MIR | 5.64E-09 7.09E-09 7.69E-09 7.94E-09 1.75E-08 2.52E-08 2.69E-08 2.76E-08 2.92E-08 | system development transcription factor activity embryonic development nucleus cell-cell adhesion cell part development cell regulation of transcription, DNA-dependent nervous system development regulation of transcription |

Table S12. Most significant p-values for families of exapted elements when the distribution of all mobile elements in the genome is used as the null distribution. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for subfamilies of exapted regions using a uniform null distribution

transcription regulator activity and related terms
development and related terms
cell adhesion and related terms

| | | cell adhesion and related terms |
|---------------|----------------------------------|--|
| subfamily | | GO term |
| MIRb | 8.53E-18 | • |
| L2 | 9.46E-18 | · |
| MIRb | 3.27E-15 | • • • |
| L2 | 5.85E-15 | |
| L2 | 2.99E-14 | |
| MER121 | 1.77E-13 | · |
| MIRb | 7.32E-13 | |
| L3_Mars | 9.38E-12 | - · · · · · · · · · · · · · · · · · · · |
| MIRb | 9.64E-12 | - |
| L2 | | transcription regulator activity |
| L3_Mars | 1.37E-11 | sequence-specific DNA binding |
| MIRb | 3.05E-11 | regulation of transcription, DNA-dependent |
| MIRb | 6.00E-11 | transcription, DNA-dependent |
| L2 | 6.27E-11 | transcription factor activity |
| MIRb | 6.57E-11 | nervous system development |
| MIR | 7.20E-11 | transcription regulator activity |
| MIRb | 7.21E-11 | regulation of cellular metabolism |
| L3 | 1.45E-10 | development |
| L2 | 1.57E-10 | DNA binding |
| L3_Mars | 1.71E-10 | transcription factor activity |
| MIRb | 1.72E-10 | regulation of metabolism |
| MIR | | development |
| L3 | 2.91E-10 | nervous system development |
| L3 | 2.97E-10 | |
| MIR | 3.65E-10 | 1 |
| MER121 | 8.32E-10 | - · · |
| MIRb | 8.37E-10 | regulation of transcription |
| MIRb | | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| MIRb | 2.04E-09 | transcription |
| MIRb | 2.22E-09 | · |
| MIRb | 3.10E-09 | |
| MIR | 3.41E-09 | <u> </u> |
| L2 | 4.90E-09 | neuron recognition |
| MER121 | | growth factor activity |
| L2 | 6.27E-09 | osteoblast differentiation |
| MIRb | | regulation of physiological process |
| L3 | 8.18E-09 | transmembrane receptor protein kinase activity |
| <u>L4</u> | 8.89E-09 | ' ' |
| <u></u> L2 | 9.33E-09 | regulation of transcription, DNA-dependent |
| MIRb | | regulation of biological process |
| MIR | 1.15E-08 | nucleic acid binding |
| MIRb | | regulation of cellular physiological process |
| MIR | 1.66E-08 | sequence-specific DNA binding |
| L2 | | regulation of transcription |
| | | embryonic epithelial tube formation |
| MIRb MIRb | | _embryonic epitnelial tube formation _neural plate morphogenesis |
| MIRb | | neural tube formation |
| | | |
| MIRb MIRb | | neural tube closure |
| MIRb | 1.80E-08 | primary neural tube formation |
| MIRb | 1.80E-08 | morphogenesis of embryonic epithelium |
| L3 | 1.97E-08 | transmembrane receptor protein tyrosine kinase activity |
| L2 | | regulation of cellular metabolism |
| L2 | 2.26E-08 | transcription, DNA-dependent |
| L2 | 2.61E-08 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| MIRb | | regulation of cellular process |
| MER121 | 3.12E-08 | morphogenesis |
| L2 | 3.34E-08 | cell glucose homeostasis |
| MIRb | 3.41E-08 | sequence-specific DNA binding |
| L2 | 4.03E-08 | cell differentiation |
| MIRb | 4.37E-08 | GPI anchor binding |
| L2 | 4.57E-08 | organ development |
| MIRb | 4.67E-08 | binding |
| | | |
| | 14.71E-08 | requiation of metapolism |
| L2 | 4.71E-08 5.01E-08 | regulation of metabolism neuron recognition |
| | 4.71E-08 5.01E-08 5.59E-08 | neuron recognition regulation of cellular metabolism |

Table S13. Most significant p-values for subfamilies of exapted elements when a uniform null over bases in the genome is used. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for subfamilies of exapted regions

using a uniform null distribution where each gene can only be selected once transcription regulator activity and related terms development and related terms cell adhesion and related terms

| subfamily L2 | 1.88E-20 | system development |
|-----------------|----------|---|
| <u></u> L2 | 1.22E-19 | 7 |
| MIRb | 2.83E-19 | · |
| MIRb | 3.22E-17 | - · |
| MIRb | 2.33E-16 | |
| | | |
| L3 | 6.15E-16 | • |
| L2 | 8.95E-16 | - · |
| MIR | | development |
| MIR | 8.07E-14 | transcription regulator activity |
| L3 | 1.91E-13 | system development |
| MIR | 2.84E-13 | transcription factor activity |
| L3 | 4.15E-13 | nervous system development |
| L3 Mars | 1.35E-12 | transcription regulator activity |
| MER121 | 1.73E-12 | development |
| MIR | 3.58E-12 | sequence-specific DNA binding |
| MIRb | | sequence-specific DNA binding |
| L2 | 1.66E-11 | |
| L2 | | |
| | 1.96E-11 | |
| L3_Mars | 4.49E-11 | |
| L3 | 5.85E-11 | cell adhesion |
| L3 Mars | 1.19E-10 | development |
| MIRb | 1.75E-10 | |
| L3_Mars | 1.89E-10 | transcription factor activity |
| MIRb | 1.95E-10 | transcription factor activity |
| MER121 | 8.74E-10 | organ development |
| MIR | 1.20E-09 | organ development |
| L3 | 1.52E-09 | transcription regulator activity |
| MIR | 1.65E-09 | binding |
| MIR Mars | | • |
| L3 Mars | 2.51E-09 | - * |
| MER121 | 3.18E-09 | |
| | | • |
| MIR Mars | | nervous system development |
| L3_Mars | 6.36E-09 | nervous system development |
| MIRm | 6.57E-09 | system development |
| L3 | 9.55E-09 | cell differentiation |
| MIR3 | 9.63E-09 | development |
| L3 | 1.12E-08 | transmembrane receptor protein kinase activity |
| L3 | 1.18E-08 | organ development |
| L3b | 1.25E-08 | sequence-specific DNA binding |
| L1ME4a | 1.36E-08 | |
| L1ME4a | | system development |
| L2 | 1.85E-08 | |
| MIRm | 1.90E-08 | , , |
| | | · |
| L2 | 2.17E-08 | central nervous system development |
| L1M5 | 2.81E-08 | • |
| MIRb | 3.60E-08 | |
| L3 Mars | | regulation of transcription, DNA-dependent |
| MER121 | 3.68E-08 | , , |
| L3 | 3.75E-08 | transcription factor activity |
| MIRb | 4.92E-08 | homophilic cell adhesion |
| L3b | 6.77E-08 | development |
| MIR Mars | | organ development |
| L3 Mars | 8.14E-08 | transcription, DNA-dependent |
| L3 | 8.42E-08 | transmembrane receptor protein tyrosine kinase activity |
| L2 | 8.85E-08 | neuron differentiation |
| MIRb | | |
| | 1.15E-07 | central nervous system development |
| L4 | 1.17E-07 | transcription regulator activity |
| L1M5 | 1.19E-07 | nervous system development |
| L3_Mars | 1.27E-07 | regulation of transcription |
| L3 | 1.40E-07 | cell-cell adhesion |
| L1M5 | 1.41E-07 | system development |
| MIR_Mars | 1.42E-07 | development |
| L2 | 1.44E-07 | organ development |
| | | |
| MIRb | 1.53E-07 | regulation of development |

Table \$14. Most significant p-values for subfamilies of exapted elements when a uniform null over genes is used and each gene can only be selected once. For an explanation of all GO tests see Supplemental Text S2.

Top GO enrichment p-values for subfamilies of exapted regions using the location of all repeat insertions as the null distribution transcription regulator activity and related terms development and related terms cell adhesion and related terms

| subfamily | n_value | cell adhesion and related terms |
|---|--|---|
| L2 | | GO term development |
| L2 | | system development |
| L2 | | nervous system development |
| MIRb | | development |
| L2 | | DNA binding |
| L3 Mars | | sequence-specific DNA binding |
| L2 | | transcription regulator activity |
| MIRb | | transcription regulator activity |
| L2 | | transcription factor activity |
| MIR | | nucleic acid binding |
| L3_Mars | | transcription regulator activity |
| MIRb | | regulation of transcription, DNA-dependent |
| L2 | | regulation of transcription, DNA-dependent |
| MIRb | 3.74E-08 | transcription, DNA-dependent |
| MIRb | | transcription factor activity |
| MIR | | transcription regulator activity |
| L2 | | regulation of transcription |
| MIRb | | regulation of cellular metabolism |
| L2 | | transcription, DNA-dependent |
| L2 | | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| MIRb | | DNA binding |
| L3_Mars | 8.98E-08 | regulation of transcription, DNA-dependent |
| MIRb | | regulation of metabolism |
| L3_Mars | 1.08E-07 | transcription factor activity |
| MIRb | 1.23E-07 | GPI anchor binding |
| L3_Mars | 1.26E-07 | transcription, DNA-dependent |
| L4 | 1.41E-07 | transcription regulator activity |
| L2 | 1.73E-07 | neuron recognition |
| MIRb | 1.80E-07 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| L2 | 1.88E-07 | regulation of cellular metabolism |
| MIR | | _DNA binding |
| L3_Mars | | regulation of transcription |
| MIRb | | regulation of transcription |
| L2 | | _transcription |
| MIRb | | _embryonic epithelial tube formation |
| MIRb | | _neural plate morphogenesis |
| MIRb | | _neural tube formation |
| MIRb | | _neural tube closure |
| MIRb | 2.42E-07 | |
| MIRb | 2.42E-07 | , , , |
| L2 | 2.65E-07 | · |
| L3 Mars | 2.81E-07 | - |
| MIR | 2.91E-07 | |
| L3_Mars | | transcription |
| MIRb MID | 3.98E-07 | · |
| MIR MIRb | 3.99E-07 | |
| MIR | 4.55E-07 | sequence-specific DNA binding |
| L3_Mars | | |
| L3_Mars_ MIR | 4.91E-07 7.00E-07 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism binding |
| HAL1b | 8.31E-07 | regulation of transcription, DNA-dependent |
| MIR | 8.50E-07 | regulation of metabolism |
| MIRb | 9.86E-07 | |
| IVIII VIV | 10.00L-07 | _nearon recognition |
| HAI 1h | | transcription DNA-dependent |
| | 1.02E-06 | ¬ · · · |
| MIRb | 1.02E-06 1.07E-06 | phosphoinositide binding |
| MIRb MIR | 1.02E-06 1.07E-06 1.14E-06 | phosphoinositide binding transcription factor activity |
| MIRb MIR L2 | 1.02E-06 1.07E-06 1.14E-06 1.54E-06 | phosphoinositide binding transcription factor activity cell recognition |
| MIRb MIR L2 MIR | 1.02E-06 1.07E-06 1.14E-06 1.54E-06 1.56E-06 | phosphoinositide binding transcription factor activity cell recognition regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| MIRb MIR L2 MIR L3_Mars | 1.02E-06 1.07E-06 1.14E-06 1.54E-06 1.56E-06 | phosphoinositide binding transcription factor activity cell recognition regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism regulation of metabolism |
| MIRb MIR L2 MIR L3 Mars L3 | 1.02E-06 1.07E-06 1.14E-06 1.54E-06 1.56E-06 1.56E-06 1.80E-06 | phosphoinositide binding transcription factor activity cell recognition regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism regulation of metabolism GPI anchor binding |
| MIR L2 MIR L3 Mars L3 MIRb | 1.02E-06 1.07E-06 1.14E-06 1.54E-06 1.56E-06 1.56E-06 1.80E-06 1.87E-06 | phosphoinositide binding transcription factor activity cell recognition regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism regulation of metabolism GPI anchor binding nervous system development |
| MIRb MIR L2 MIR L3 Mars L3 MIRb HAL1b | 1.02E-06 1.07E-06 1.14E-06 1.54E-06 1.56E-06 1.56E-06 1.80E-06 1.87E-06 1.94E-06 | phosphoinositide binding transcription factor activity cell recognition regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism regulation of metabolism GPI anchor binding nervous system development transcription regulator activity |
| MIRb MIR L2 MIR L3 Mars L3 MIRb | 1.02E-06 1.07E-06 1.14E-06 1.54E-06 1.56E-06 1.56E-06 1.80E-06 1.87E-06 | phosphoinositide binding transcription factor activity cell recognition regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism regulation of metabolism GPI anchor binding nervous system development transcription regulator activity cell glucose homeostasis |

Table S15. Most significant p-values for subfamilies of exapted elements when the distribution of all mobile elements in the genome is used as the null distribution. For an explanation of all GO tests see Supplemental Text S2.

Table S16. The largest clusters of exapted elements and a nearby gene they may regulate

| Chrom | #Elements | Region (Mb) | Gene | Gene function |
|-------|-----------|-------------|----------|---|
| 11 | 44 | 1.57 | ODZ4 | signaling and transcription regulation during development |
| 11 | 40 | 1.32 | HNT | cell adhesion and neurite outgrowth |
| 18 | 37 | 1.24 | BRUNOL4 | developmental splicing regulation |
| 3 | 35 | 1.07 | EPHB1 | guidance receptor for neuronal connectivity |
| 2 | 32 | 1.04 | Unknown | Ünknown |
| 9 | 31 | 1.00 | FCMD | migration and assembly of neurons |
| 9 | 31 | 1.00 | CDK5RAP2 | regulation of neuronal differentiation |
| 13 | 31 | 1.00 | DIAPH3 | cellular motility, adhesion, and cytokinesis |
| 10 | 30 | 1.00 | CRTAC1 | cell adhesion |

This table lists chromosomal location and abundance of the densest 1Mb locales in the human genome for surveyed CNE exaptations. These regions most often overlap large gene deserts (Figure 4), presumably there to harbor the regulatory regions governing the expression of a nearby, most often developmental gene. The putative target genes are often involved in neuronal development, which is clearly seen in this short list.

Table S17. Enrichment of all exaptations for annotated pathways

| P-value | Pathway |
|-------------|--|
| 4.57611e-05 | Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy pathway |
| 0.00010284 | Wnt Signaling Pathway |
| 0.000109369 | ALK in cardiac myocytes pathway |
| 0.000571029 | G Protein Signaling Pathways |
| 0.000952423 | Reelin reception |
| 0.0016645 | Corticosteroids and cardioprotection pathway |
| 0.0016645 | Effects of calcineurin in Keratinocyte Differentiation pathway |
| 0.00204904 | Chondroitin / Heparan sulfate biosynthesis |
| 0.00256153 | Reelin Signaling Pathway pathway |
| 0.0034129 | Calcium Channels |
| 0.00349215 | Signaling Pathway from G-Protein Families pathway |
| 0.00368649 | Nuclear Receptors |
| 0.00398588 | Cell Cycle G1 S Check Point pathway |
| 0.0069549 | Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells pathway |
| 0.0074094 | Pertussis toxin-insensitive CCR5 Signaling in Macrophage pathway |
| 0.00752601 | Control of skeletal myogenesis by HDAC and calcium calmodulin-dependent kinase CaMK pathway |
| 0.010302 | Cell to Cell Adhesion Signaling pathway |
| 0.0121154 | CXCR4 Signaling Pathway pathway |
| 0.0125916 | TGF Beta Signaling Pathway |
| 0.0131346 | Fc Epsilon Receptor I Signaling in Mast Cells pathway |
| 0.0131346 | Signaling of Hepatocyte Growth Factor Receptor pathway |
| 0.0163225 | Ca Calmodulin-dependent Protein Kinase Activation pathway |
| 0.0188365 | Function of SLRP in Bone An Integrated View pathway |
| 0.0210557 | nos1Pathway pathway |
| 0.0212401 | Regulation of Spermatogenesis by CREM pathway |
| 0.0217451 | WNT Signaling Pathway pathway |
| 0.0217918 | Erk1 Erk2 Mapk Signaling pathway pathway |
| 0.0282009 | Galactose metabolism |
| 0.0306238 | NFAT and Hypertrophy of the heart Transcription in the broken heart pathway |
| 0.0308757 | Alpha-synuclein and Parkin-mediated proteolysis in Parkinson's disease pathway |
| 0.0346002 | O-Glycans biosynthesis |
| 0.0347328 | The IGF-1 Receptor and Longevity pathway |
| 0.0358894 | Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages pathway |
| 0.0364711 | Role of Tob in T-cell activation pathway |
| 0.036641 | Regulation of BAD phosphorylation pathway |
| 0.036641 | Regulation of PGC-1a pathway |
| 0.036641 | Monoamine GPCRs |
| 0.0377373 | p38 MAPK Signaling Pathway pathway |
| 0.0394605 | MAPKinase Signaling Pathway pathway |
| 0.0402183 | Bioactive Peptide Induced Signaling Pathway pathway |
| 0.0445893 | Gamma-aminobutyric Acid Receptor Life Cycle pathway |
| 0.0448973 | Actions of Nitric Oxide in the Heart pathway |
| 0.045102 | T Cell Receptor Signaling Pathway pathway |
| 0.0478432 | Inhibition of Cellular Proliferation by Gleevec pathway |

This test used a uniform null over genes and each gene could be selected at most once. The p-values will show if our whole set of exaptations is enriched for a certain pathway that has been annotated.

Table S18. Enrichment of classes, families, and subfamilies of exapted elements for annotated pathways

| level | name | p-value | Pathway |
|-------------|-------------|-------------|--|
| subfamily | MIRm | 3.58086e-06 | Signaling Pathway from G-Protein Families pathway |
| family | L1 | 4.44207e-06 | Reelin reception |
| subfamily | MIRb | 6.7485e-06 | Reelin reception |
| class | LINE | 2.73547e-05 | Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy pathway |
| subfamily | L1MC4_3endX | 4.37259e-05 | Signaling of Hepatocyte Growth Factor Receptor pathway |
| class | SINE | 4.94168e-05 | G Protein Signaling Pathways |
| family | MIR | 4.94168e-05 | G Protein Signaling Pathways |
| class | SINE | 5.76333e-05 | Reelin reception |
| family | MIR | 5.76333e-05 | Reelin reception |
| class | SINE | 6.30211e-05 | Wnt Signaling Pathway |
| family | MIR | 6.30211e-05 | Wnt Signaling Pathway |
| subfamily | MLT1K | 0.00010579 | ALK in cardiac myocytes pathway |
| subfamily | MIRm | 0.000108228 | Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells pathway |
| family | L1 | 0.000139029 | Reelin Signaling Pathway pathway |
| subfamily | MLT1K | 0.000158219 | p38 MAPK Signaling Pathway pathway |
| subfamily | MIRm | 0.000190758 | Actions of Nitric Oxide in the Heart pathway |
| subfamily | MIRb | 0.000208574 | Reelin Signaling Pathway pathway |
| subfamily | MIRm | 0.000282139 | Endocytotic role of NDK Phosphins and Dynamin pathway |
| class | LINE | 0.000314906 | Reelin reception |
| class | LTR | 0.000328462 | ALK in cardiac myocytes pathway |
| subfamily | L1MC | 0.000339889 | Reelin reception |
| class | LINE | 0.000342128 | ALK in cardiac myocytes pathway |
| family | L2 | 0.000371015 | ALK in cardiac myocytes pathway |
| subfamily | L2 | 0.000371015 | ALK in cardiac myocytes pathway |
| family | MaLR | 0.000401576 | ALK in cardiac myocytes pathway |
| class | SINE | 0.000461285 | Signaling Pathway from G-Protein Families pathway |
| family | MIR | 0.000461285 | Signaling Pathway from G-Protein Families pathway |
| family | L1 | 0.0004647 | Signal Dependent Regulation of Myogenesis by Corepressor MITR pathway |
| family | L2 | 0.00046567 | Chondroitin / Heparan sulfate biosynthesis |
| subfamily | L2 | 0.00046567 | Chondroitin / Heparan sulfate biosynthesis |
| class | LINE | 0.000470695 | Chondroitin / Heparan sulfate biosynthesis |
| subfamily | L1ME3 | 0.000486647 | Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa alpha pathway |
| class | SINE | 0.00050867 | Effects of calcineurin in Keratinocyte Differentiation pathway |
| family | MIR | 0.00050867 | Effects of calcineurin in Keratinocyte Differentiation pathway |
| subfamily | MIR | 0.000522392 | Effects of calcineurin in Keratinocyte Differentiation pathway |
| subfamily | MIRm | 0.000563079 | Fc Epsilon Receptor I Signaling in Mast Cells pathway |
| subfamily | L1ME4a | 0.000582401 | GPCRs Class B Secretin-like |
| subfamily | MIRm | 0.000611983 | G Protein Signaling Pathways |
| subfamily | HAL1 | 0.00064503 | p53 Signaling Pathway pathway |
| subfamily | MIRm | 0.000666856 | nos1Pathway pathway |
| class | LINE | 0.000696149 | Reelin Signaling Pathway pathway |
| subfamily | HAL1 | 0.000030143 | Cell Cycle Control in G1/S Phase |
| subfamily | MLT1E3 | 0.000793611 | GATA3 participate in activating the Th2 cytokine genes expression pathway |
| subfamily | MLT2C1 | 0.000793611 | GATA3 participate in activating the Th2 cytokine genes expression pathway |
| subfamily | L1M1 | 0.000793011 | GPCRs Class A Rhodopsin-like |
| family | CR1 | 0.000790139 | Nuclear Receptors |
| family | MaLR | 0.000857272 | TGF beta signaling pathway pathway |
| family | MaLR | 0.00083304 | TGF Beta Signaling Pathway TGF Beta Signaling Pathway |
| subfamily | L1M5 | 0.000869185 | Signal Dependent Regulation of Myogenesis by Corepressor MITR pathway |
| subfamily | MER70B | 0.000900048 | Blood Clotting Cascade |
| Subiditilly | IVIER/UD | 0.000942414 | blood Clotting Cascade |

This test used a uniform null over genes and each gene could be selected at most once. The p-values will show if any class, family, or subfamily of our set of exaptations is enriched for a certain pathway that has been annotated.

Table S19. Exaptations from our set that have overlaps with verified developmental enhancers

| chrom | start | end | name | length | lengthOfConfirmed |
|-------|----------|----------|----------|--------|-------------------|
| chr1 | 50807508 | 50807558 | exap212 | 50bp | 1743bp |
| chr11 | 32154993 | 32155091 | exap1484 | 98bp | 1244bp |
| chr16 | 70962838 | 70962939 | exap3631 | 101bp | 3058bp |

We compared our set of putative cis-regulatory elements exapted from mobile elements to verified developmental enhancers. The above three exaptations out of our set of 10402 have overlaps with verified enhancers available through the Enhancer Browser [4]. In the last column we show the length of the overlapping region that has been verified as a developmental enhancer. Due to the fact that these validated regions are so much larger, it is not clear if our exaptation is the entire, part of, or outside the functional unit.

Table S20. Overlaps with human and mouse CAGE tags

| #overlaps | enrichment | tissue | species |
|-----------|------------|----------------------|---------|
| 1 | 3.16x | cerebral cortex | mouse |
| 1 | 1.91× | diencephalon | mouse |
| 1 | 1.91× | epididymis | human |
| 1 | 1.08× | renal artery | human |
| 2 | 6.10× | mammary gland | human |
| 2 | 1.99× | prostate gland | human |
| 2 | 2.16× | prostate gland | mouse |
| 2 | 1.45× | testis | mouse |
| 2 | 2.26× | ureter | human |
| 2 | 0.40× | urinary bladder | human |
| 3 | 6.37× | heart | mouse |
| 4 | 1.78× | undefined tissue | mouse |
| 4 | 0.79× | adipose | mouse |
| 4 | 2.54× | brain | mouse |
| 5 | 0.86× | pancreas | human |
| 5 | 1.19× | rectum | human |
| 5 | 1.71× | somatosensory cortex | mouse |
| 6 | 0.99× | kidney | human |
| 6 | 0.83× | small intestine | human |
| 6 | 1.93× | visual cortex | mouse |
| 7 | 2.05× | cerebellum | mouse |
| 13 | 0.63× | cecum | human |
| 13 | 1.57× | embryo | mouse |
| 20 | 0.85× | adipose | human |
| 22 | 2.16× | macrophage | mouse |
| 24 | 0.99× | undefined tissue | human |
| 25 | 0.76× | large intestine | human |
| 25 | 1.58× | liver | mouse |
| 33 | 2.25× | lung | mouse |
| 34 | 1.25× | liver | human |
| 53 | 1.12x | cerebrum | human |
| 120 | 2.12x | all tissues pooled | mouse |
| 183 | 1.06× | all tissues pooled | human |
| 297 | 1.34× | all tissues pooled | both |

CAGE sequencing can identify uncommon transcription start sites that may be tissue or time specific. We investigated the intersection of our set with CAGE data that recently became available, but no significant enrichments with a decent sample size were found. Many CAGE tags that did not map uniquely to the genome were discarded, so possibly the full contribution of interspersed repeats acting as alternative start sites is not being realized. While some of the exaptations in our set may act as alternative start sites for neighboring genes, we believe the vast majority function as cis-regulatory elements.

Table S21. GO Enrichment for elements contributing to peaks of conservation

| subfamily | peak | p-value | GO term |
|-----------|-------|-------------|--|
| L2 | peak4 | 1.70521e-06 | development |
| L3 | peak3 | 1.87747e-06 | nervous system development |
| L3 | peak3 | 2.01658e-06 | system development |
| L2 | peak4 | 6.96576e-06 | nervous system development |
| L2 | peak4 | 7.36326e-06 | system development |
| L2 | peak2 | 1.74886e-05 | positive regulation of receptor mediated endocytosis |
| L3 | peak3 | 2.28994e-05 | homophilic cell adhesion |
| L2 | peak4 | 2.50304e-05 | transcription regulator activity |
| L2 | peak4 | 2.74366e-05 | sequence-specific DNA binding |
| L2 | peak4 | 2.77285e-05 | homophilic cell adhesion |
| L2 | peak2 | 3.08003e-05 | DNA replication factor A complex |
| L2 | peak1 | 3.57795e-05 | regulation of MAPK activity |
| L2 | peak1 | 3.90588e-05 | steroid hormone receptor activity |
| L2 | peak3 | 4.36072e-05 | axon guidance receptor activity |
| L2 | peak1 | 4.67597e-05 | skeletal muscle development |
| L2 | peak1 | 4.67597e-05 | muscle fiber development |
| L2 | peak1 | 4.69023e-05 | ligand-dependent nuclear receptor activity |
| L3 | peak3 | 5.48026e-05 | ligand-regulated transcription factor activity |
| L3 | peak3 | 5.98758e-05 | transmembrane receptor protein tyrosine kinase activity |
| L2 | peak4 | 6.95206e-05 | transcription factor activity |
| L2 | peak4 | 7.18001e-05 | ureteric bud development |
| L3 | peak3 | 7.66953e-05 | potassium ion binding |
| L3 | peak2 | 8.81003e-05 | neuron recognition |
| L2 | peak2 | 9.20735e-05 | replication fork (sensu Eukaryota) |
| L2 | peak2 | 9.20735e-05 | replisome (sensu Eukaryota) |
| L2 | peak1 | 0.000103508 | vesicular fraction |
| L2 | peak3 | 0.000106477 | receptor activity |
| L2 | peak4 | 0.000114908 | specific RNA polymerase II transcription factor activity |
| L2 | peak1 | 0.000116145 | ephrin receptor activity |
| L3 | peak3 | 0.000117494 | regulation of transcription, DNA-dependent |

Most significant GO enrichments for elements contributing to the peaks of preferential exaptation in the L2 and L3 consensus sequences. These peaks of preferential exaptation are defined in Figure 2 of the main text. The L2 element (Figure 2A) has four peaks and the L3 element (Figure 2B) has three peaks. Peaks are numbered from left to right.

Table S22. Pathway enrichment for elements contributing to peaks of conservation

| subfamily | peak | p-value | Pathway |
|-----------|-------|-------------|--|
| L3 | peak3 | 7.37409e-05 | Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy pathway |
| L2 | peak4 | 0.000102791 | Nuclear Receptors |
| L2 | peak1 | 0.000180276 | Androgen and estrogen metabolism |
| L2 | peak1 | 0.00029759 | 1 4-Dichlorobenzene degradation |
| L2 | peak1 | 0.000436606 | G13 Signaling Pathway |
| L3 | peak2 | 0.000440204 | Corticosteroids and cardioprotection pathway |
| L2 | peak1 | 0.000495958 | Tetrachloroethene degradation |
| L2 | peak1 | 0.000694307 | Alkaloid biosynthesis I |
| L3 | peak2 | 0.000793611 | GATA3 participate in activating the Th2 cytokine genes expression pathway |
| L2 | peak1 | 0.000892636 | Methane metabolism |
| L2 | peak3 | 0.000951098 | Multi-step Regulation of Transcription by Pitx2 pathway |
| L2 | peak1 | 0.000991793 | Nucleotide GPCRs |
| L2 | peak1 | 0.000991793 | Flavonoids stilbene and lignin biosynthesis |
| L2 | peak2 | 0.00187986 | Chondroitin / Heparan sulfate biosynthesis |
| L2 | peak1 | 0.00218265 | G Protein Signaling Pathways |
| L3 | peak3 | 0.00218265 | IGF-1 Signaling Pathway pathway |
| L3 | peak2 | 0.00231703 | Glycogen Metabolism |
| L3 | peak2 | 0.0025283 | ALK in cardiac myocytes pathway |
| L2 | peak1 | 0.00267671 | Bile acid biosynthesis |
| L2 | peak3 | 0.00310825 | Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages pathway |
| L2 | peak1 | 0.00396216 | Tumor Suppressor Arf Inhibits Ribosomal Biogenesis pathway |
| L3 | peak1 | 0.00396216 | Ion Channel and Phorbal Esters Signaling Pathway pathway |
| L3 | peak1 | 0.00396216 | Phospholipase C d1 in phospholipid associated cell signaling pathway |
| L2 | peak1 | 0.00415965 | Glucocorticoid and Mineralcorticoid Metabolism |
| L2 | peak3 | 0.0044561 | Eph Kinases and ephrins support platelet aggregation pathway |
| L3 | peak1 | 0.00475282 | g-Secretase mediated ErbB4 Signaling Pathway pathway |
| L2 | peak1 | 0.0053456 | Sprouty regulation of tyrosine kinase signals pathway |
| L2 | peak2 | 0.00534758 | Glycogen Metabolism |
| L2 | peak4 | 0.00589178 | GPCRs Class B Secretin-like |
| L2 | peak4 | 0.00594058 | HIV-1 defeats host-mediated resistance by CEM15 pathway |

Most significant GO enrichments for elements contributing to the peaks of preferential exaptation in the L2 and L3 consensus sequences. These peaks of preferential exaptation are defined in Figure 2 of the main text. The L2 element (Figure 2A) has four peaks and the L3 element (Figure 2B) has three peaks. Peaks are numbered from left to right.

Table S23. Groups of exaptations with high sequence similarity

| clique | chrom | start | end | name |
|----------|-------|-----------|-----------|-----------|
| clique1 | | | | |
| CiiquCI | chr10 | 8684835 | 8685220 | exap936 |
| | chr18 | 53007470 | 53007671 | exap4255 |
| | chr2 | 80116457 | 80116672 | exap4750 |
| | chr2 | 114811708 | 114811968 | exap4807 |
| | chr3 | 136994724 | 136994988 | exap 1007 |
| | chr5 | 165696963 | 165697116 | exap7708 |
| | chr8 | 106583914 | 106584260 | exap7700 |
| | chr9 | 81545776 | 81546019 | exap9526 |
| clique2 | Cili | 01313110 | 01310013 | схарээго |
| ciiquez | chr1 | 6766244 | 6766378 | exap5 |
| | chr1 | 36778713 | 36778982 | exap109 |
| | chr14 | 99928779 | 99929072 | exap3047 |
| | chr15 | 55737165 | 55737374 | exap3163 |
| | chr17 | 67835017 | 67835349 | exap3966 |
| | chr5 | 92669061 | 92669406 | exap7440 |
| | chr5 | 177644035 | 177644205 | exap7710 |
| clique3 | Cili | 177011033 | 177011203 | схарттот |
| Ciiques | chr10 | 8684835 | 8685220 | exap936 |
| | chr8 | 106583914 | 106584260 | exap9330 |
| | chr9 | 81545776 | 81546019 | exap9131 |
| clique4 | Citi | 013 +3//0 | 013 10019 | C/UP3020 |
| Ciique i | chr1 | 107144025 | 107144173 | exap510 |
| | chr10 | 115273519 | 115273717 | exap1293 |
| | chr11 | 19664983 | 19665165 | exap1437 |
| | chr11 | 79530571 | 79530719 | exap1649 |
| | chr11 | 114504075 | 114504252 | exap1755 |
| | chr11 | 115568338 | 115568460 | exap1733 |
| | chr18 | 33405926 | 33406103 | exap4097 |
| | chr20 | 39066823 | 39067075 | exap5501 |
| | chr3 | 138892127 | 138892327 | exap6344 |
| | chr6 | 116374148 | 116374323 | exap8134 |
| clique5 | Cilio | 110374140 | 110374323 | слароточ |
| ciiques | chr10 | 115273519 | 115273717 | exap1293 |
| | chr14 | 69465869 | 69466011 | exap2910 |
| | chr22 | 33715412 | 33715545 | exap5694 |
| | chr20 | 39066823 | 39067075 | exap5501 |
| | chr18 | 33405926 | 33406103 | exap4097 |
| | chr8 | 119321831 | 119321989 | exap9195 |
| | chr11 | 79530571 | 79530719 | exap3133 |
| | chr11 | 19664983 | 19665165 | exap1437 |
| | chr12 | 76755392 | 76755554 | exap2228 |
| | chr7 | 147324503 | 147324609 | exap8804 |
| | chr9 | 8162033 | 8162218 | exap9339 |
| | chr10 | 86432276 | 86432453 | exap1149 |
| | chr20 | 49610156 | 49610280 | exap5565 |
| | chr18 | 35310049 | 35310264 | exap4135 |
| | chr20 | 14549693 | 14549878 | exap 1133 |
| | chr11 | 114504075 | 114504252 | exap1755 |
| | chr18 | 34138838 | 34139057 | exap4121 |
| | chr6 | 116374148 | 116374323 | exap8134 |
| | chr11 | 115568338 | 115568460 | exap0131 |
| | chr11 | 96296033 | 96296233 | exap1709 |
| | chr2 | 233419675 | 233419834 | exap5339 |
| | chr1 | 80586846 | 80587042 | exap369 |
| | chr3 | 138892127 | 138892327 | exap6344 |
| | chr11 | 128966346 | 128966568 | exap1890 |
| | chr2 | 211371345 | 211371436 | exap1030 |
| | chr1 | 87886389 | 87886581 | exap428 |
| | chr16 | 24179203 | 24179333 | exap3458 |
| | C 10 | 2.113200 | | S/100 |

These five cliques consist of groups of sequences that may or may not have come from the same consensus, but are all similar to each other at the sequence level. We expect that these exaptations, since they all have sequence similarity to each other, may all have similar functions. Some cliques are contained in others. The larger sets were made when we relaxed the threshold for sequence similarity. We investigated the enrichment of these cliques for being near genes with similar GO annotation or pathway annotation (Table S24, Table S25, Table S26, and Table S27).

Table S24. Top GO enrichments for exaptations with similar sequence composition, assuming a uniform null over bases

| clique | p-value | GO term |
|---------|-------------|--|
| clique5 | 0.000121181 | RNA interference |
| clique5 | 0.000128404 | RNA-mediated gene silencing |
| clique5 | 0.000128404 | RNA-mediated posttranscriptional gene silencing |
| clique5 | 0.000128404 | posttranscriptional gene silencing |
| clique5 | 0.000132331 | translation repressor activity |
| clique5 | 0.000234344 | germ cell development |
| clique2 | 0.000277744 | specific RNA polymerase II transcription factor activity |
| clique5 | 0.000384721 | gene silencing |
| clique2 | 0.000735728 | tryptophan-tRNA ligase activity |
| clique2 | 0.000735728 | tryptophanyl-tRNA aminoacylation |
| clique5 | 0.00141147 | embryonic development |
| clique4 | 0.00143248 | DNA topoisomerase type I activity |
| clique4 | 0.00202342 | DNA topoisomerase (ATP-hydrolyzing) activity |
| clique3 | 0.00213054 | regulation of transcription, DNA-dependent |
| clique3 | 0.00223043 | transcription, DNA-dependent |
| clique4 | 0.00243573 | DNA topoisomerase activity |
| clique3 | 0.00233803 | regulation of transcription |
| clique3 | 0.00244173 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| clique4 | 0.00245744 | DNA topological change |
| clique3 | 0.00272773 | transcription |

Table S23 shows the exaptations that make up each clique. We see no strong enrichments using the GO annotation of nearby genes and the enrichment test that assumes a uniform null over bases.

Table S25. Top GO enrichments for exaptations with similar sequence composition, assuming a uniform null over genes

| clique | p-value | GO term |
|---------|-------------|--|
| clique2 | 0.000108018 | specific RNA polymerase II transcription factor activity |
| clique4 | 0.000430383 | susceptibility to natural killer cell mediated cytotoxicity |
| clique2 | 0.000580352 | tryptophan-tRNA ligase activity |
| clique2 | 0.000580352 | tryptophanyl-tRNA aminoacylation |
| clique4 | 0.00124042 | BRE binding |
| clique4 | 0.00124042 | positive regulation of cell killing |
| clique4 | 0.00124042 | positive regulation of immune cell mediated cytotoxicity |
| clique4 | 0.00124042 | positive regulation of natural killer cell mediated cytotoxicity |
| clique4 | 0.00124042 | translation repressor activity, nucleic acid binding |
| clique5 | 0.00141058 | carbamoyl-phosphate synthase (ammonia) activity |
| clique5 | 0.00141058 | susceptibility to natural killer cell mediated cytotoxicity |
| clique4 | 0.00185005 | RNA interference |
| clique4 | 0.00185005 | regulation of natural killer cell mediated cytotoxicity |
| clique3 | 0.0020314 | regulation of transcription, DNA-dependent |
| clique3 | 0.00222354 | transcription, DNA-dependent |
| clique2 | 0.00244544 | ligand-regulated transcription factor activity |
| clique3 | 0.00243173 | regulation of transcription |
| clique4 | 0.00231542 | DNA topoisomerase type I activity |
| clique4 | 0.00231542 | RNA-mediated gene silencing |
| clique4 | 0.00231542 | RNA-mediated posttranscriptional gene silencing |

Table S23 shows the exaptations that make up each clique. We see no strong enrichments using the GO annotation of nearby genes and the enrichment test that assumes a uniform null over genes.

Table S26. Top pathway enrichments for exaptations with similar sequence composition, assuming a uniform null over bases

| clique | p-value | pathway |
|---------|------------|--|
| clique3 | 0.00341244 | GATA3 participate in activating the Th2 cytokine genes expression pathway |
| clique1 | 0.00507357 | GATA3 participate in activating the Th2 cytokine genes expression pathway |
| clique1 | 0.0184214 | Glycogen Metabolism |
| clique2 | 0.0244434 | Nuclear Receptors |
| clique5 | 0.0244385 | Role of MEF2D in T-cell Apoptosis pathway |
| clique2 | 0.0273532 | Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa alpha pathway |
| clique5 | 0.030254 | GATA3 participate in activating the Th2 cytokine genes expression pathway |
| clique5 | 0.0332134 | Effects of calcineurin in Keratinocyte Differentiation pathway |
| clique5 | 0.0341383 | BCR Signaling Pathway pathway |
| clique5 | 0.0354481 | Calcium Channels |
| clique5 | 0.0355802 | Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells pathway |
| clique5 | 0.0355844 | fMLP induced chemokine gene expression in HMC-1 cells pathway |
| clique5 | 0.0455133 | Fc Epsilon Receptor I Signaling in Mast Cells pathway |

Table S23 shows the exaptations that make up each clique. We see no strong enrichments using the pathway annotation of nearby genes and the enrichment test that assumes a uniform null over bases.

Table S27. Top pathway enrichments for exaptations with similar sequence composition, assuming a uniform null over genes

| clique | p-value | pathway |
|---------|------------|---|
| clique3 | 0.00237504 | GATA3 participate in activating the Th2 cytokine genes expression pathway |
| clique1 | 0.00334285 | GATA3 participate in activating the Th2 cytokine genes expression pathway |
| clique1 | 0.0124343 | Glycogen Metabolism |
| clique2 | 0.0131214 | Nuclear Receptors |
| clique5 | 0.0181044 | GATA3 participate in activating the Th2 cytokine genes expression pathway |
| clique5 | 0.0203433 | Effects of calcineurin in Keratinocyte Differentiation pathway |
| clique5 | 0.0203433 | Role of MEF2D in T-cell Apoptosis pathway |
| clique2 | 0.0205513 | Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa alpha pathway |
| clique5 | 0.0235241 | Calcium Channels |
| clique5 | 0.0281455 | Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells pathway |
| clique5 | 0.0323825 | Control of skeletal myogenesis by HDAC and calcium calmodulin-dependent kinase CaMK pathway |
| clique5 | 0.033853 | BCR Signaling Pathway pathway |
| clique5 | 0.038057 | Signaling Pathway from G-Protein Families pathway |
| clique5 | 0.038057 | fMLP induced chemokine gene expression in HMC-1 cells pathway |
| clique5 | 0.0351543 | Fc Epsilon Receptor I Signaling in Mast Cells pathway |
| clique5 | 0.0402543 | Chondroitin / Heparan sulfate biosynthesis |
| clique5 | 0.0437443 | T Cell Receptor Signaling Pathway pathway |

Table S23 shows the exaptations that make up each clique. We see no strong enrichments using the pathway annotation of nearby genes and the enrichment test that assumes a uniform null over genes.

Table S28. Entropy of exaptation clouds

| nearby | cloud | entropy | cloud | relative entropy |
|----------|---------|----------|------------------|------------------|
| gene | entropy | p-value | relative entropy | p-value |
| ODZ4 | 4.22394 | 0.071512 | 0.800085 | 0.31728 |
| HNT | 3.78582 | 0.757998 | 0.759496 | 0.434821 |
| BRUNOL4 | 3.61931 | 0.886686 | 0.680547 | 0.740578 |
| EPHB1 | 4.10043 | 0.167666 | 1.74524 | 2e-06 |
| Unknown | 3.68071 | 0.680444 | 1.18375 | 0.080675 |
| FCMD | 3.70311 | 0.523548 | 0.956758 | 0.476443 |
| CDK5RAP2 | 3.63825 | 0.719776 | 0.790847 | 0.692403 |
| DIAPH3 | 3.30954 | 0.974321 | 1.21726 | 0.072967 |
| CRTAC1 | 3.88485 | 0.381596 | 1.03452 | 0.167772 |

The clusters, or clouds, of exaptation as defined in Table S16 and shown in Figure 4 were analyzed for their entropy and relative entropy to see if genes were exapting multiple copies of the same element, or trying to acquire one of each. The p-values for getting an entropy that high with the given number of elements in the cloud are based on a simulation. We could not see a general trend across the largest clouds (clusters) of exaptations.




Fig. S1. Location of the boreoeutherian ancestor We have highlighted the location of the boreoeutherian ancestor on a species tree with a red asterix. We insist that all our conserved elements be present in human, chimp, rhesus, rat, mouse and dog so the elements pre-date the boreoeutherian ancestor. By similar logic, we only include repeat subfamilies that have copies in the same six species, and therefore were active before, or during, the boreoeutherian ancestor. We term these subfamilies to be "pan-boreoeutherian."




Fig. S2. Preferential exaptation of specific portions of mobile elements. For each base in the mobile element consensus (x-axis) the relative abundance is plotted (y-axis). The abundance throughout the entire genome is shown in gray and the abundance that has come under strong purifying selection for a nonexonic function is in red. (A) MER117 is a putative non-autonomous DNA transposon [1] that shows preferential 5' propensity to CNE exaptation. (B) MIR_Mars is a SINE [1] that shows preferential 3' CNE exaptation, while its tRNA derived 5'-end, responsible for Pol III transcription initiation in SINEs [12], is depleted.




Fig. S3. Putative engrailed (En-1) binding sites near all known cellular response genes in the reelin-signaling pathway. All four genes known to play a cellular role in the reelin receptor pathway have an insertion of a MIRb element near them, which has subsequently come under strong purifying selection. These four MIRb elements contain multiple predicted binding sites for En-1, Oct-1 (Pou2f1), SRY, v-Myb, and YY1, each orthologously conserved back to dog. We have aligned together orthologous copies of each of the four paralogs, from six different species, anchored to the consensus sequence of the progenitor MIRb (top). Each genomic sequence is labeled with the gene it is thought to regulate as well as the species it is from. We show a section of the alignment that is rich in potential binding sites for En-1. Each En-1 binding site is shown in dark blue and orthologously conserved instances have a light blue rectangle connecting them. Each paralog appears to conserve multiple binding sites from the original sequence, but not necessarily the same ones. The cases of Oct-1, SRY, v-Myb, and YY1 are qualitatively similar.

Detectability Of Mobile Element Families Following Extinction




Fig. S4. Evolutionary distance needed for an extinct repeat family to vanish. We investigated how long a family can be detected after ceasing to replicate itself. The apparent population size of the repeat in the extant human genome will depend upon how large the family was when it stopped replicating and how long it has been since replication stopped. If the death of the element happened at the speciation of human and dog, then almost all elements will clearly align to each other in the extant genome. If the element stopped jumping at the speciation of human and opossum, then the element will be less obvious, but the numbers should be large enough to notice that a repeat once existed and it may be reconstructed. If the death was before the speciation of human and chicken then the element can most likely not be detected in the present human genome. The surface is colored green when over 100 elements will significantly align to a member of the family, yellow when over 35 elements will align, and red when less than 35 elements will align.